All conditions

Head and Neck Cancer

Plain English clinical trial information, updated daily from ClinicalTrials.gov and public government registries. Not medical advice.

2724
Trials on record
516
Recruiting now
7
Australian sites
77
Phase 3 trials
How these figures are counted
  • Trials on record is every trial tagged to this condition at any stage, except those withdrawn before starting or terminated early. Most are completed rather than ongoing, so this is a measure of research history, not of current activity. It is also smaller than the sitewide "trials tracked" figure, which does include withdrawn and terminated trials.
  • Recruiting now counts only trials whose registry status is "Recruiting". Trials listed as not yet recruiting or enrolling by invitation are excluded, so this understates how many may open to new participants soon.
  • Australian sites counts trials counted under "Recruiting now" that list at least one Australian site. A site being listed does not mean it is currently enrolling, and Australian trials registered only on ANZCTR are not counted yet, so this understates local availability.
  • Phase 3 trials counts trials counted under "Recruiting now" that are at Phase 3.

Find recruiting trials for Head and Neck Cancer →

Get alerts when Head and Neck Cancer trials change ↗

Voxsanity currently covers 103 conditions. We are expanding coverage regularly.

Understanding Head and Neck Cancer

Head and neck cancer is a broad term for cancers that develop in the tissues and organs of the head and neck area. This includes the mouth, throat, voice box (larynx), salivary glands, nasal passages, and sinuses. Most of these cancers start in the cells that line the moist surfaces inside the head and neck, such as the inside of the mouth or throat. The type of cancer a person has depends on exactly where in the head and neck area it begins.

In Australia, head and neck cancers account for around 4,500 new diagnoses each year, making them among the more common cancer groups in the country. They are more frequently diagnosed in men than women, and tend to occur more often in people over the age of 50. Key risk factors include smoking, alcohol use, and infection with certain strains of the human papillomavirus (HPV). However, people without any of these risk factors can still be diagnosed.

Treatment for head and neck cancer varies depending on the type, size, and location of the cancer, as well as the person's overall health. Common approaches include surgery to remove the tumour, radiation therapy, chemotherapy, or a combination of these. In some cases, targeted drug therapies may also be used. Because the head and neck region is involved in essential functions like speaking, swallowing, and breathing, a team of different specialists typically works together to plan care. This team often includes surgeons, radiation oncologists, medical oncologists, speech therapists, and dietitians.

This overview is an AI generated summary written from public medical sources and checked on a sample basis. It is general information, not medical advice or a diagnosis. Always speak with your doctor about your situation. How we use AI

Can you access treatment for Head and Neck Cancer in Australia right now? Here's what's publicly known.

Information on this site does not constitute medical advice. Data is sourced from publicly available government registries. Always consult your doctor before making any health decisions. Trial status should be verified directly with the trial site.

Updated regularly from public government registries

Research pipeline

Where trials for Head and Neck Cancer currently sit in the development pipeline. The funnel shape shows how few drugs reach later phases in general; the counts are this condition's actual trial numbers.

Phase success rates are industry-wide historical averages, not predictions for specific trials. Learn how trials work →

Most active research sponsors

Organisations with the most recruiting trials for Head and Neck Cancer.

View sponsor profile
View sponsor profile
View sponsor profile
View sponsor profile
View sponsor profile

Where trials are running

Clinical trial sites for Head and Neck Cancer by country. Australia is highlighted.

Showing the top 10 of 56 countries with trial sites.

Clinical trials for Head and Neck Cancer

Showing 519 of 519 trials

The plain English eligibility text on each trial below is an AI generated summary of the official criteria, checked on a sample basis. How we use AI

🇦🇺 NCT04266223 · University of Sydney Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 November 2024
🇦🇺 AU

Who might be able to join this trial: - You have been diagnosed with head and neck cancer, at any stage - You are 18 years of age or older - You are reasonably active and able to care for yourself, even if you cannot do heavy physical work (confirm with trial site) - You are currently receiving radiation therapy for he...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
🇦🇺 NCT04534205 · BioNTech SE Phase 3 · 23 countries Recruiting
Recruiting Phase 3 Est. completion 1 April 2029
🇦🇷 AR🇦🇺 AU🇦🇹 AT🇧🇪 BE🇧🇷 BR🇨🇦 CA🇨🇱 CL🇨🇿 CZ +15 more

**Who might be able to join this trial:** - People who have signed a consent form before any pre-screening steps take place. - People who have been diagnosed through laboratory testing with head and neck cancer (specifically squamous cell carcinoma) that has come back or spread, is linked to a virus called HPV16, and...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT04901234 · Centre hospitalier de l'Université de Montréal (CHUM) Phase 2 · 2 countries Recruiting
Recruiting Phase 2 Est. completion 1 December 2024
🇦🇺 AU🇨🇦 CA

Who might be able to join this trial: - Adults aged 18 or older - People who are able to give written agreement to take part in the trial - People diagnosed with a specific stage of throat cancer (stage T3 or T4, with or without spread to nearby lymph nodes, as classified by a standard medical staging system) - People...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT05025813 · Queensland Health Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 June 2025
🇦🇺 AU

**Who might be able to join this trial:** - People who have been diagnosed (confirmed by laboratory tissue analysis) with a serious form of skin cancer called invasive cutaneous squamous cell carcinoma (cSCC) that is at an advanced local stage, has been assessed before surgery as high-risk, and where the medical team...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT06029270 · National Cancer Institute (NCI) Phase 2 · 5 countries Recruiting
Recruiting Phase 2 Est. completion 30 April 2029
🇦🇺 AU🇨🇦 CA Hong Kong🇸🇬 SG🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with nasopharyngeal carcinoma (a type of cancer in the back of the nose and throat) that has come back in the same area or spread to other parts of the body, or who were first diagnosed when the cancer had already spread. - People whose cancer...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT06256588 · GlaxoSmithKline Phase 3 · 31 countries Recruiting
Recruiting Phase 3 Est. completion 30 June 2028
🇦🇷 AR🇦🇺 AU🇧🇪 BE🇧🇷 BR🇨🇦 CA🇨🇳 CN🇨🇿 CZ🇫🇷 FR +23 more

**Who might be able to join this trial:** - You have been newly diagnosed with a specific type of head and neck cancer (called HNSCC) affecting the mouth, throat, voice box, or lower throat area, which cannot be surgically removed, and you have already completed a full course of chemotherapy (using a drug called cispl...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT06525220 · Merus B.V. Phase 3 · 28 countries Recruiting
Recruiting Phase 3 Est. completion 1 January 2028
🇦🇷 AR🇦🇺 AU🇧🇪 BE🇧🇷 BR🇨🇦 CA🇨🇱 CL🇭🇷 HR🇨🇿 CZ +20 more

**Who might be able to join this trial:** - People who have signed a consent form before any study procedures begin - People aged 18 years or older at the time of signing the consent form - People with a laboratory-confirmed diagnosis of head and neck squamous cell cancer (a specific type of head and neck cancer) that...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT01403064 · CSL Behring Phase 2 · 6 countries Terminated
Terminated Phase 2 Est. completion 1 April 2013
🇦🇺 AU🇦🇹 AT🇨🇦 CA🇩🇪 DE🇮🇹 IT🇺🇸 US

**Who might be able to join this trial:** - You have been recently diagnosed (within the last 6 months) with a type of cancer called squamous cell carcinoma (a specific type of cancer) in the mouth, throat, or voice box area, confirmed by a biopsy, and it has not spread to other parts of the body - Your cancer will be...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT03452137 · Hoffmann-La Roche Phase 3 · 23 countries Terminated
Terminated Phase 3 Est. completion 27 September 2023
🇦🇺 AU🇧🇪 BE🇧🇷 BR🇨🇦 CA🇨🇳 CN🇫🇷 FR🇩🇪 DE🇭🇺 HU +15 more

**Who might be able to join this trial:** - You have been diagnosed with squamous cell carcinoma of the head and neck (a specific type of cancer affecting the head and neck area), confirmed by a lab test. - Your HPV (Human Papillomavirus) status has been tested and is known. - You have already completed your main canc...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT04428333 · GlaxoSmithKline Phase 3 · 19 countries Terminated
Terminated Phase 3 Est. completion 27 April 2021
🇦🇷 AR🇦🇺 AU🇧🇪 BE🇧🇷 BR🇨🇦 CA🇩🇰 DK🇫🇷 FR🇩🇪 DE +11 more

Who might be able to join this trial: - People aged 18 or older who are able to give their agreement to take part after being fully informed about the trial. - People diagnosed with head and neck squamous cell cancer (a specific type of cancer affecting the mouth, throat, voice box, or part of the throat called the hyp...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT00200486 · Montefiore Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2030
🇺🇸 US

Who might be able to join this trial: - People who have a known or suspected tumour in the head or neck area, whether or not it is cancerous - People who are scheduled to have a biopsy or surgical removal of a tumour, or who already have stored tumour tissue samples available for non-genetic testing Who may not be abl...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT00230308 · Stanford University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2030
🇺🇸 US

Who might be able to join this trial: - People who are having surgery for head and neck cancer at Stanford University. Who may not be able to join: - People whose surgery is taking place at a hospital or medical centre other than Stanford University. Important: Always verify eligibility with the trial site directly b...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT00568490 · Stanford University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2027
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with squamous cell carcinoma (a type of cancer) of the head and neck, or non-small cell lung cancer, confirmed by laboratory testing of tissue samples — or family members of people with a confirmed diagnosis of squamous cell carcinoma of the head an...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT00898638 · Vanderbilt University Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2050
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with head and neck cancer - People who are currently receiving cancer treatment at Vanderbilt University Medical Center - People who are healthy (without cancer) and wish to participate as a healthy volunteer Who may not be able to join: - No speci...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT01269190 · M.D. Anderson Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2028
🇺🇸 US

Who might be able to join this trial: - Adults who have growths or sores in the mouth and are already scheduled to have surgery or a biopsy in the head and neck area to remove or examine those growths. - People who have already received previous treatment for their condition may still be considered. - People who are ab...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT01473784 · Ohio State University Comprehensive Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇺🇸 US

Who might be able to join this trial: - People who need diagnostic or treatment procedures for non-cancerous or cancerous conditions of the mouth or throat area, including tumours of the tongue, tongue base, tonsils, palate, parts of the throat, or the voice box (larynx) - People whose mouth and throat can be opened wi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT01958762 · Centre Hospitalier Universitaire, Amiens Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2028
🇫🇷 FR

"Who might be able to join this trial: - You must be a smoker who has bought at least one pack of cigarettes from a tobacco shop in the Somme area during a two-week period - You must live in the Somme department (a region in northern France) Who may not be able to join: - No specific exclusion criteria have been liste...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT01985984 · Maastricht Radiation Oncology Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2030
🇳🇱 NL

Who might be able to join this trial: - People who are scheduled to receive radiotherapy with the goal of curing their condition, either as the main treatment or after surgery Who may not be able to join: - People who are scheduled to receive radiotherapy aimed at managing symptoms or improving comfort, rather than cu...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02128906 · Christopher Wilke Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 16 December 2031
🇺🇸 US

Who might be able to join this trial: - You have been diagnosed with a specific type of throat or voice box cancer (squamous cell carcinoma, undifferentiated carcinoma, or poorly differentiated carcinoma) located in the oropharynx, larynx, or hypopharynx, confirmed by a biopsy, with no sign that the cancer has spread t...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT02139020 · Cliniques universitaires Saint-Luc- Université Catholique de Louvain Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2033
🇧🇪 BE

Who might be able to join this trial: - People who have received radiation therapy combined with cetuximab (a targeted cancer drug) following a specific treatment approach known as the Bonner protocol - People who have received cetuximab combined with chemotherapy following a specific treatment approach known as the Ve...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02290145 · Shanghai Jiao Tong University School of Medicine Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2024
🇨🇳 CN

**Who might be able to join this trial:** - People aged between 18 and 75 years old. - Both men and women are eligible. - People with a reasonable level of general health and ability to carry out daily activities (confirmed by a doctor using a standard health scoring tool). - People who have had a tissue sample (biops...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT02572778 · Cliniques universitaires Saint-Luc- Université Catholique de Louvain Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2025
🇧🇪 BE

Who might be able to join this trial: - People who have been diagnosed with head and neck cancer for the first time, or whose cancer has come back or spread to other parts of the body. - People who are about to have surgery or a tissue sample (biopsy) taken from their tumour. - People whose medical records include deta...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02584270 · University of Michigan Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2028
🇺🇸 US

Who might be able to join this trial: - You have recently been diagnosed with an early-stage cancer of the tongue (known as T1 or T2 stage) for the first time. Who may not be able to join: - Your tongue cancer has come back after previous treatment (recurrent disease). - You have had radiation therapy to your head or...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02678884 · University Health Network, Toronto Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2028
🇨🇦 CA

**Who might be able to join this trial:** - People diagnosed with squamous cell carcinoma (a type of cancer) in the head and neck area, specifically in the moist inner lining of these areas, but not in the nasopharynx (the upper part of the throat behind the nose) - People whose scans show visible signs of active disea...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02734537 · ECOG-ACRIN Cancer Research Group Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2027
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with squamous cell carcinoma (a type of cancer) of the head and neck — specifically in the oral cavity, oropharynx, hypopharynx, or larynx — at stage III or IVA, confirmed by laboratory testing - People whose cancer is located in the oropharynx...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03010150 · M.D. Anderson Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2028
🇺🇸 US

Who might be able to join this trial: - People who are planned to receive radiation treatment aimed at curing cancer of the nasopharynx, oropharynx, hypopharynx, larynx, or an unknown primary cancer that has spread to lymph nodes in the neck - People with oropharyngeal (throat) cancer not related to HPV (human papillom...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03117946 · Centre Hospitalier Universitaire de Besancon Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 29 August 2026
🇫🇷 FR

**Who might be able to join this trial:** - People who have been diagnosed with non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), or head and neck cancer, confirmed by a laboratory test of tissue samples - People whose treatment plan involves radiation therapy and chemotherapy given at the same time, a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03215719 · NYU Langone Health Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2028
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with squamous cell carcinoma (a type of cancer) of the oropharynx — this includes cancers of the tonsil, base of tongue, soft palate, or back wall of the throat, confirmed by a tissue or cell sample. - People whose tissue sample has tested posi...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03238378 · University of Erlangen-Nürnberg Medical School Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2022
🇩🇪 DE

Who might be able to join this trial: - People who have a head and neck cancer that has come back (recurred), confirmed by a tissue sample analysis - People whose returning cancer is classified as an early-to-intermediate stage (rcT1-3, meaning the tumour is not the most advanced size) - People whose tumour is located...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03326947 · Shanghai Jiao Tong University School of Medicine Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 January 2026
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with squamous cell carcinoma (a type of cancer) in your mouth — specifically in the tongue, gums, cheek lining, floor of the mouth, palate, or the area behind the back teeth - You are between 18 and 75 years old - You can be male or female - You are ge...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03353467 · Sun Yat-sen University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2025
🇨🇳 CN

**Who might be able to join this trial:** - People who have been newly diagnosed with nasopharyngeal carcinoma (a type of cancer in the back of the nose/throat) confirmed by a biopsy, specifically classified as WHO Type II or III, and at Stage I (early stage) - People who have not received any previous treatment for th...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03385720 · Guang-Yan Yu Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2023
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with early-stage squamous cell carcinoma (a type of cancer) that started in the mouth, specifically classified as T1N0 or T2N0 (meaning the tumour is relatively small and has not spread to nearby lymph nodes or other parts of the body) **Who ma...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03394417 · National University Hospital, Singapore Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇸🇬 SG

**Who might be able to join this trial:** - People who are 21 years of age or older - People who have a confirmed tissue-based diagnosis of head and neck cancer - People who are due to receive chemotherapy and radiation therapy at the same time - People whose general health and ability to carry out daily activities fal...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03396718 · Technische Universität Dresden Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 November 2029
🇩🇪 DE

**Who might be able to join this trial:** - People who have had surgery to remove a squamous cell carcinoma (a type of cancer) from the oropharynx (the middle part of the throat, including the base of the tongue and tonsils), along with appropriate removal of nearby lymph nodes - People whose medical team has recommen...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03406247 · Gustave Roussy, Cancer Campus, Grand Paris Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 November 2027
🇫🇷 FR

**Who might be able to join this trial:** - People who have had a return of head and neck squamous cell cancer (or a new primary cancer) in an area of the body that was previously treated with radiation at a dose of 50 Gray or more. - People whose cancer affects the mouth, throat (oro- or hypopharynx), or voice box (l...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03480971 · Matrix Biomed, Inc. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 July 2025
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 or older who have been medically diagnosed with squamous cell cancer of the head and neck - People who are scheduled to receive radiotherapy or proton therapy aimed at curing their cancer - People who are receiving the chemotherapy drug cisplatin as part of th...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03481647 · Göteborg University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇸🇪 SE

Who might be able to join this trial: - People who are scheduled to receive a full course of radiation therapy aimed at curing their cancer, where the treatment field includes the major saliva-producing glands in the head/neck area Who may not be able to join: - People whose cancer has come back after previous treatme...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03632200 · Centre Hospitalier Universitaire, Amiens Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2027
🇫🇷 FR

"Who might be able to join this trial: - You have been diagnosed with a cancer of the upper aerodigestive tract (the area including the mouth, throat, and related structures) - You are a man or woman aged 18 or older - You are scheduled to have surgery as part of your cancer treatment - You are willing and able to sign...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03649048 · London Health Sciences Centre Research Institute OR Lawson Research In... Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2028
🇨🇦 CA

**Who might be able to join this trial:** - People aged 18 or older - People who are willing and able to sign a written consent form - People whose general health and ability to carry out daily activities falls within a certain range, as measured by a standard cancer performance scale (ECOG score of 0–2) - People who...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03708224 · Alain Algazi Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 June 2028
🇺🇸 US

**Who might be able to join this trial:** - People who have a suspected squamous cell cancer of the head and neck that doctors believe can be surgically removed with the goal of curing or treating the disease. - People who are willing and able to sign a written consent form agreeing to take part in the trial. - People...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03736863 · The First Affiliated Hospital of Zhengzhou University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 20 June 2021
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 75 years, of any gender. - People who have been diagnosed with oesophageal squamous cell cancer (a specific type of oesophageal cancer) through a tissue or cell sample, where the cancer is advanced, cannot be surgically removed, and has either spread to nea...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03751566 · Masaryk Memorial Cancer Institute Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 4 September 2023
🇨🇿 CZ

Who might be able to join this trial: - People receiving radiotherapy aimed at curing or reducing the chance of head and neck cancer returning after treatment - People with a moderate level of ability to carry out daily activities (not fully active, but not completely dependent on others for care) - People who are will...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03829033 · Lund University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2028
🇸🇪 SE

**Who might be able to join this trial:** - People who are at least 18 years old - People who have been diagnosed with a specific type of cancer called squamous cell carcinoma of the tonsil, confirmed by a tissue or cell sample, that has not been treated before, and is at an early to intermediate stage (as classified...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03875716 · Dana-Farber Cancer Institute Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2027
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with a specific type of throat cancer (squamous cell carcinoma) affecting the tonsil, base of the tongue, or an unknown primary site, confirmed by a tissue or cell sample - Your cancer is linked to HPV (human papillomavirus), confirmed by specific lab...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03919552 · Nanfang Hospital, Southern Medical University Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 31 December 2025
🇨🇳 CN

**Who might be able to join this trial:** - People who have been newly diagnosed with a specific type of nasopharyngeal cancer called "non-keratinizing" (confirmed by tissue biopsy, based on World Health Organization classification) - People whose cancer has been staged as locally advanced (T3-4 with any lymph node in...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03952065 · Second Affiliated Hospital of Guangzhou Medical University Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 January 2029
🇨🇳 CN

**Who might be able to join this trial:** - A tissue or cell sample (biopsy) has confirmed a diagnosis of head and neck cancer. - The person is aged between 18 and 80 years old and is expected to live for more than 3 months. - The person is generally well enough to carry out light activity and care for themselves (ass...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03975322 · University of Erlangen-Nürnberg Medical School Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 December 2024
🇩🇪 DE

**Who might be able to join this trial:** - People aged 18 to 80 years old - Both men and women are eligible - People who have been diagnosed with one or more white patches (leukoplakia) in the mouth, including cases where the white patches are linked to a condition called lichen planus, OR are linked to an immune syst...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03997643 · London Health Sciences Centre Research Institute OR Lawson Research In... Phase 2 · 4 countries Recruiting
Recruiting Phase 2 Est. completion 1 September 2026
🇨🇦 CA🇮🇪 IE🇬🇧 GB🇺🇸 US

**Who might be able to join this trial:** - People who are willing to give their formal agreement to participate in the study - People who are generally able to carry out daily activities with little to no limitation (this is measured using a standard medical scale called ECOG, with scores 0–2) - People who have been...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04003051 · M.D. Anderson Cancer Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2026
🇺🇸 US

Who might be able to join this trial: - People who are currently receiving radiation treatment aimed at curing throat cancer - People who can read and speak English or Spanish well enough to complete questionnaires and understand website content Who may not be able to join: - No specific exclusion criteria were listed...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04019548 · Jules Bordet Institute Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 November 2027
🇧🇪 BE

Who might be able to join this trial: - Adults aged 18 or older - People of any gender - People who have been newly diagnosed with a specific type of throat cancer (squamous cell carcinoma of the oropharynx), confirmed by a tissue sample (biopsy) - People whose cancer has not spread to distant parts of the body and for...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04099290 · UNC Lineberger Comprehensive Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 February 2027
🇺🇸 US

**Who might be able to join this trial:** - You must be willing to sign a consent form agreeing to take part in the study and allowing your personal health information to be used - You must agree to allow researchers to use leftover tissue from your biopsy or surgery, and to have blood samples taken at regular interval...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04104945 · AHS Cancer Control Alberta Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 21 October 2028
🇨🇦 CA

**Who might be able to join this trial:** - People aged 18 or older - People who are able to give informed consent to participate - People with a performance status rating of 0–2 on the ECOG scale, meaning they are fully active or able to carry out light activity (confirm with trial site) - People whose cancer has bee...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04151082 · M.D. Anderson Cancer Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 July 2027
🇺🇸 US

Who might be able to join this trial: - Adult survivors of oropharyngeal cancer (for the clinical trial) or head and neck cancer (for the registry) who currently show no signs of cancer. - People who finished radiation treatment at least 2 years ago, confirmed through scans and medical check-ups. - People who have dev...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04166006 · Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. I... Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 April 2027
🇮🇹 IT

Who might be able to join this trial: - People who have been diagnosed (confirmed by laboratory testing of tissue) with stage IV Head and Neck Squamous Cell Carcinoma, Neuroendocrine Tumors, or Soft Tissue Sarcoma, and who have had surgery aimed at fully removing the cancer. - People whose surgical tissue sample was su...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04178174 · Centre hospitalier de l'Université de Montréal (CHUM) Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 December 2027
🇨🇦 CA

**Who might be able to join this trial:** - You are 18 years of age or older - You are able to read and sign a consent form agreeing to take part in the study - You are generally able to carry out daily activities, with at most some limitations due to your condition (confirm with trial site) - You have been diagnosed t...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04185974 · University Hospital Heidelberg Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 July 2030
🇩🇪 DE

**Who might be able to join this trial:** - People whose head and neck cancer has come back or grown in the same area after they previously received radiation treatment - People who still have some cancer cells remaining (either visible or microscopic) after surgery to remove the tumour - People whose doctors have det...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04191460 · Erasmus Medical Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 May 2025
🇳🇱 NL

**Who might be able to join this trial:** - People who have been diagnosed with squamous cell carcinoma (a type of cancer) of the mouth, confirmed by a tissue biopsy, and whose cancer is suitable for surgical removal - People who are 18 years of age or older - People who have given written consent to participate before...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04214366 · Heidelberg University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2027
🇩🇪 DE

**Who might be able to join this trial:** - People who have been diagnosed with a type of cancer called adenoid cystic carcinoma located in the head and neck area, confirmed through a tissue sample (biopsy) - People whose cancer meets at least one of these treatment conditions: the tumour cannot be surgically removed,...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04217512 · Sherief Abd-Elsalam Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 December 2030
🇪🇬 EG

Who might be able to join this trial: - People who have been diagnosed with head and neck cancer Who may not be able to join: - People whose kidneys are not filtering blood well enough (a kidney function score below 59, measured by a test called GFR) - People who have diabetes - People whose liver enzyme levels are mo...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04277858 · Nader Sadeghi Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 August 2024
🇨🇦 CA

**Who might be able to join this trial:** - People diagnosed with a specific type of throat cancer (squamous cell cancer of the oropharynx) that tests positive for a protein called p16 - People whose cancer is at a certain stage — classified as Stage III or Stage IVa under a standard cancer staging system (confirm wit...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04333537 · NRG Oncology Phase 3 · 2 countries Recruiting
Recruiting Phase 3 Est. completion 27 April 2031
🇨🇦 CA🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed (confirmed by tissue or cell testing) with squamous cell carcinoma (a type of cancer) in the mouth area — this includes the tongue, floor of the mouth, inner lip, inner cheek, lower or upper gum ridge, the area behind the back molars, or the ro...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04375384 · Wake Forest University Health Sciences Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2026
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with a type of cancer called head and neck squamous cell carcinoma, confirmed through a tissue or cell sample test. - You have at least one tumor or affected area that can be measured on a scan. - You have already received a type of cancer treatment ca...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04376866 · Cancer Hospital of Guangxi Medical University Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 April 2023
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with nasopharyngeal carcinoma (a type of cancer in the back of the nose/throat) that has come back, confirmed either by a tissue biopsy or by two or more imaging scans (MRI and PET-CT) - People whose cancer has been assessed as a specific stage...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04428515 · Sunnybrook Health Sciences Centre Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 23 April 2024
🇨🇦 CA

**Who might be able to join this trial:** - People with head and neck cancer that has been confirmed by laboratory testing of a tissue or cell sample, has not yet received any first-line treatment, and is planned to be treated with radiotherapy. - People whose cancer can be measured by ultrasound or MRI scan done withi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04436965 · Sun Yat-sen University Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 December 2026
🇨🇳 CN

Who might be able to join this trial: - People who have been newly diagnosed with nasopharyngeal carcinoma (a type of head and neck cancer) confirmed by a tissue sample, specifically WHO types II or III - People of any gender aged between 18 and 65 years old - People who have a good general level of physical functionin...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04437329 · Affiliated Cancer Hospital & Institute of Guangzhou Medical University Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 30 June 2028
🇨🇳 CN

**Who might be able to join this trial:** - People who have been newly diagnosed with a specific type of nasopharyngeal carcinoma (a cancer of the upper throat area behind the nose), confirmed by tissue testing, classified as WHO Type II or III (non-keratinizing) - People whose cancer has been staged as Stage III or I...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04448522 · Sun Yat-sen University Phase 3 · 2 countries Recruiting
Recruiting Phase 3 Est. completion 1 August 2026
🇨🇳 CN🇸🇬 SG

**Who might be able to join this trial:** - People who have been diagnosed with a specific type of nose and throat cancer called non-keratinizing nasopharyngeal carcinoma (a particular subtype confirmed by tissue testing) - People whose cancer has been classified as a certain stage (Stage II or III) based on how far i...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04452162 · Abramson Cancer Center at Penn Medicine Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2026
🇺🇸 US

**Who might be able to join this trial:** - You have a growth or lump in one of your salivary glands (the glands that produce saliva) that is at least 1 cm³ in size - You have never received any treatment before for this salivary gland growth **Who may not be able to join:** - You have a history of any type of cancer...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04453813 · Sun Yat-sen University Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 July 2025
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with nasopharyngeal carcinoma (a type of cancer at the back of the nose) that has come back, confirmed by a tissue sample test - People whose cancer came back more than 12 months after finishing their first course of radiation treatment - Peopl...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04453826 · Sun Yat-sen University Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 September 2026
🇨🇳 CN

**Who might be able to join this trial:** - People diagnosed with a specific type of nasopharyngeal cancer (a cancer at the back of the nose/throat) confirmed by a tissue sample — specifically the non-keratinizing type (WHO type II or III). - People whose cancer has been classified as a certain advanced stage (stage I...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04470024 · Providence Health & Services Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 31 December 2027
🇺🇸 US

**Who might be able to join this trial:** - People who have head and neck squamous cell carcinoma (a type of cancer affecting the mouth, throat, or related areas) that has come back or spread to other parts of the body. - People aged 18 or older. - People whose general physical condition is reasonably functional — rat...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04511078 · University of Alabama at Birmingham Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2030
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with squamous cell carcinoma (a type of cancer) in the head or neck area, confirmed by a biopsy - Your cancer can be at any stage and in any part of the head or neck, including cases where the cancer has come back or is a new cancer in a different loc...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04564989 · UNC Lineberger Comprehensive Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2033
🇺🇸 US

Who might be able to join this trial: - Adults aged 18 or older - People with a specific stage of cancer in the throat (back of mouth/tonsil area) or from an unknown starting point in the head and neck, based on a standard staging system used by doctors (confirm with trial site) - People whose cancer has been confirmed...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04567056 · Aalborg University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2025
🇩🇰 DK

Who might be able to join this trial: **Cancer Group (people with a cancer diagnosis):** - People who are able to provide written agreement to take part in the trial - People who have been diagnosed with a specific type of cancer affecting the head and neck area (called head and neck squamous cell carcinoma) **Contro...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04593589 · University Medical Center Groningen Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 January 2026
🇳🇱 NL

**Who might be able to join this trial:** - People diagnosed with squamous cell carcinoma (a type of cancer) that started in the lining of the mouth - People who have had surgery to remove the tumour, including removal of nearby lymph nodes on the same side of the neck - People who are planned to receive radiation the...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04611113 · Fondazione IRCCS Policlinico San Matteo di Pavia Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 November 2026
🇮🇹 IT

**Who might be able to join this trial:** - People who have been diagnosed with head or neck cancer - People for whom doctors have recommended chemotherapy combined with radiation therapy, either as a main treatment or as a follow-up treatment after surgery - People who are available to attend the planned measurements...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04612075 · Norwegian University of Science and Technology Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2025
🇳🇴 NO

**Who might be able to join this trial:** - People who are willing and able to give full written consent as required by the ethics committee overseeing the study - People who have been diagnosed with squamous cell carcinoma (a specific type of cancer) in the head and neck area, including the throat, voice box, mouth, o...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04671667 · National Cancer Institute (NCI) Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 June 2029
🇺🇸 US

**Who might be able to join this trial:** - People between 18 and 79 years of age - People who have head and neck squamous cell cancer (in the mouth, throat, voice box, or lower throat area) that has come back or is a new primary cancer in an area that was previously treated with radiation - People who have had surger...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04671940 · Royal Marsden NHS Foundation Trust Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 7 October 2026
🇬🇧 GB

Who might be able to join this trial: - People who are over 18 years old - People who have previously had a head and neck cancer that was treated with radiation therapy - People who are having a type of throat surgery (performed with a robot through the mouth) as part of their treatment for a head and neck cancer that...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04681469 · Gruppo Oncologico del Nord-Ovest Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 June 2023
🇮🇹 IT

**Who might be able to join this trial:** - Adults aged 18 or older of any gender - People who have given written consent to participate in the study - People diagnosed with a specific type of mouth or throat cancer (squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx) that has been confirme...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04722523 · Memorial Sloan Kettering Cancer Center Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 20 June 2026
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with squamous cell carcinoma (a type of cancer) of the head and neck, confirmed by a tissue or cell sample, where the cancer started in the mouth, throat, nasal cavity, sinuses, voice box, or the area just below the throat - People whose cancer...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04778956 · Sun Yat-sen University Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 3 March 2025
🇨🇳 CN

**Who might be able to join this trial:** - The cancer came back more than 6 months after finishing radiation treatment. - A tissue biopsy has confirmed that the cancer is a recurrent (returned) nasopharyngeal carcinoma (a type of cancer in the back of the nose/throat area). - The tumor in the nasopharynx area is at a...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04805528 · University of Rochester Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 May 2028
🇺🇸 US

**Who might be able to join this trial:** - People who are over 18 years of age - People of any gender or ethnicity - People who are able and willing to attend ALTENS therapy sessions over a 12-week period - People who have previously received radiation treatment to the head and neck area at a dose greater than 50 Gy -...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04809324 · Dr.Pankaj Chaturvedi Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇮🇳 IN

Who might be able to join this trial: - People who have been diagnosed with oral cavity squamous cell cancer (a type of mouth cancer) through a biopsy, have not yet received any treatment, and are planned for surgery to remove the tumour with clear margins around it - People whose tumour can be fully assessed before su...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04852328 · Washington University School of Medicine Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 October 2027
🇺🇸 US

**Who might be able to join this trial:** - People who have been confirmed (through laboratory testing of tissue or cells) to have squamous cell carcinoma of the oropharynx (throat/tonsil area), or a lump in the upper neck without a known origin that doctors suspect comes from the oropharynx. - People whose cancer is...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04875611 · Maria Sklodowska-Curie National Research Institute of Oncology Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2025
🇵🇱 PL

**Who might be able to join this trial:** - You are over 18 years old - Your cancer has been confirmed by a tissue or cell sample to be squamous cell carcinoma - Your cancer started in the nasopharynx (the upper part of the throat, behind the nose) - Your cancer did not respond to, or got worse during, a previous plat...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04892173 · Johnson & Johnson Enterprise Innovation Inc. Phase 3 · 27 countries Recruiting
Recruiting Phase 3 Est. completion 30 June 2028
🇦🇹 AT🇧🇪 BE🇧🇷 BR🇧🇬 BG🇨🇦 CA🇨🇳 CN🇭🇷 HR🇨🇿 CZ +19 more

**Who might be able to join this trial:** - You are 60 years of age or older - You have been diagnosed through a biopsy with a type of cancer called squamous cell carcinoma, located in the mouth, throat, or upper part of the voice box area - Your cancer is at a certain advanced stage, as confirmed by your doctor using...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04908696 · Eye & ENT Hospital of Fudan University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 23 June 2026
🇨🇳 CN

**Who might be able to join this trial:** - People diagnosed with laryngeal cancer (affecting the voice box, including the glottic, supraglottic, or subglottic areas) or hypopharyngeal cancer (affecting the lower throat, including the pyriform sinus, postcricoid, or posterior pharyngeal wall areas) - People with cance...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04966481 · Washington University School of Medicine Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 28 February 2028
🇺🇸 US

**Who might be able to join this trial:** - People diagnosed with a specific type of head and neck cancer (squamous cell carcinoma of the oral cavity, larynx, or hypopharynx, or certain types affecting the throat or neck) that is not linked to HPV, confirmed through a tissue or cell sample. - People whose cancer has a...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04969926 · National Institute of Diabetes and Digestive and Kidney Diseases (NIDD... Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 22 January 2031
🇺🇸 US

Who might be able to join this trial: - People who are known to have, suspected of having, or considered at risk of developing a parathyroid condition or a related disorder. - People who are 6 months of age or older. Who may not be able to join: - Infants who are 6 months of age or younger. - People with other health...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04988074 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 June 2027
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with HPV-positive squamous cell cancer of the throat/mouth area (specifically the oropharynx), confirmed by a laboratory test. - People whose cancer has been confirmed as specifically caused by the HPV16 strain of the virus (other HPV types are...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05030597 · Zhongnan Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2025
🇨🇳 CN

Who might be able to join this trial: - People who are willing to take part and have signed a consent form agreeing to participate - People aged between 18 and 70 years old - People who have a strong clinical suspicion of oral cancer, or whose oral cancer has come back after previous treatment (newly diagnosed patients...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05031910 · Thomas Jefferson University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 February 2027
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with cancer in the head and neck area, specifically in the mouth, throat, voice box, or the area just below the throat (with a tumour stage ranging from T1 to T4) - People who are receiving their cancer care at Thomas Jefferson University – Cent...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05044117 · Sun Yat-sen University Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 October 2026
🇨🇳 CN

**Who might be able to join this trial:** - You are generally healthy and able to carry out daily activities with little or no limitation (your doctor may refer to this as ECOG performance status 0 or 1). - You have been newly diagnosed with a confirmed squamous cell cancer (a specific type of cancer) of the mouth, th...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05069857 · Shanghai Jiao Tong University School of Medicine Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 August 2024
🇨🇳 CN

Who might be able to join this trial: - Adults between 18 and 75 years old, of any gender - People who are able to carry out daily activities with little to no limitation (as measured by a standard health scale called ECOG, with a score of 0 to 2) - People who have been confirmed by a tissue biopsy to have a specific t...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05082961 · Centre Francois Baclesse Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2028
🇫🇷 FR

**Who might be able to join this trial:** - People aged 18 or older - People who have had surgery for a head and neck cancer (including cancers of the upper throat and airway, nasopharynx, facial sinuses, skull base, or brain) - People whose surgery either fully removed the tumour, or left only a very small amount tha...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05108090 · Indiana University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2026
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 or older at the time of signing the consent form - People who are able to give written consent to take part in the study - People who have a primary (new) or returning invasive skin cancer called cutaneous squamous cell carcinoma, located on the head or neck,...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05125055 · Shanghai Jiao Tong University School of Medicine Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 30 September 2024
🇨🇳 CN

**Who might be able to join this trial:** - People aged between 18 and 75 years old - Both men and women may be considered - People whose general health and ability to carry out daily activities falls within an acceptable range, as assessed by their doctor using a standard scale (confirm with trial site) - People with...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05126160 · Zhejiang Cancer Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2022
🇨🇳 CN

**Who might be able to join this trial:** - People who have been recently diagnosed with a specific type of cancer (non-keratinizing or keratinizing carcinoma), confirmed by a tissue sample (biopsy) - People who are generally well enough to carry out light activity and care for themselves (a doctor will assess this us...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05147844 · Xinqiao Hospital of Chongqing Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2025
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 75 years old - People who have been diagnosed with nasopharyngeal carcinoma (a type of cancer in the back of the nose and throat) confirmed by laboratory testing of tissue or cell samples - People whose cancer has spread to other parts of the body (metastat...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05156060 · Natalie Lockney Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2025
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with head and neck cancer confirmed by a tissue sample (biopsy). - People whose cancer is locally advanced and has not spread to distant parts of the body, based on specific staging categories (confirm with trial site for exact staging details). - P...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05172245 · National Cancer Institute (NCI) Phase 1 · 2 countries Recruiting
Recruiting Phase 1 Est. completion 1 July 2027
🇨🇦 CA🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with a confirmed squamous cell cancer of the head and neck (including cancers of the throat, voice box, mouth, nasal cavity, sinuses, or an unknown primary site in the head and neck), with disease that can be measured on scans according to standard...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05192655 · Charite University, Berlin, Germany Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2025
🇩🇪 DE

Who might be able to join this trial: - You are over 18 years old and have been diagnosed with a type of head and neck cancer (called HNSCC), and you are being treated at the Charité hospital's Radiation Oncology or Oral and Maxillofacial Surgery department - Your treatment plan is aimed at curing the cancer (such as r...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05200650 · IntraGel Therapeutics Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 15 May 2025
🇮🇱 IL

**Who might be able to join this trial:** - Adults between 18 and 80 years old (male or female) - People who are willing to follow the study procedures throughout the trial - People who are mentally able to understand the trial and sign a consent form on their own - People who have been diagnosed with a primary head a...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05260671 · Eye & ENT Hospital of Fudan University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 25 December 2024
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 or older, of any gender - People who have been diagnosed with squamous cell carcinoma of the head and neck (a specific type of cancer affecting the mouth, throat, voice box, or lower throat area), confirmed by a tissue biopsy - People whose cancer has come bac...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05272696 · Guangdong Provincial People's Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 January 2026
🇨🇳 CN

**Who might be able to join this trial:** - People diagnosed with a specific type of head and neck cancer (squamous cell carcinoma of the oral cavity, oropharynx, larynx, or hypopharynx) that is at an advanced local stage (Stage III or IVA) and has not spread to other parts of the body, confirmed by tissue or cell tes...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05283226 · NATCO Pharma Ltd. Phase 2 · 2 countries Recruiting
Recruiting Phase 2 Est. completion 30 December 2026
🇮🇳 IN🇺🇸 US

**Who might be able to join this trial:** - People who are willing and able to understand and sign a consent form, and agree to follow the study requirements. - People aged 18 or older at the time of signing consent. - People who have been diagnosed by tissue biopsy with head and neck cancer (in the oral cavity, throa...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05296109 · Chinese University of Hong Kong Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2027
Hong Kong

Who might be able to join this trial: - People who have been found to have a parotid gland tumour (a growth near the jaw/ear area) through an imaging scan such as an ultrasound or CT scan, with or without a prior needle biopsy result, and who are attending an ear, nose and throat specialist clinic. Who may not be able...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05296941 · Dalarna County Council, Sweden Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2029
🇸🇪 SE

Who might be able to join this trial: - Adults aged 18 or older who have been diagnosed by a doctor with leukoplakia, erythroplakia, or proliferative verrucous leukoplakia (these are conditions that cause patches or changes in the lining of the mouth) Who may not be able to join: - People who are not able to read and...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05305131 · National University Hospital, Singapore Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 28 December 2025
🇸🇬 SG

**Who might be able to join this trial:** - People aged 21 or older who have given written consent to take part (or whose legal representative has done so on their behalf) - People who have been diagnosed with a specific type of nose and throat cancer called non-keratinizing nasopharyngeal carcinoma (NPC), confirmed t...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05307939 · Memorial Sloan Kettering Cancer Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 24 March 2027
🇺🇸 US

**Who might be able to join this trial:** - Adults aged 18 or older - People with a performance status rating of 0–2 on the ECOG scale, meaning they are fully active or able to carry out light activity (confirm with trial site) - People diagnosed with HPV-16 related squamous cell cancer of the throat/tonsil area (orop...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05317000 · Barbara Burtness Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 June 2028
🇺🇸 US

**Who might be able to join this trial:** - People diagnosed with a specific type of throat cancer (squamous cell carcinoma of the oropharynx) that can be surgically removed, confirmed by a tissue or cell sample from the tumor or a nearby lymph node. - People whose cancer is at an early-to-moderate stage (T1-T3, N0-N2...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05319483 · University of Pecs Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2024
🇭🇺 HU

"Who might be able to join this trial: - You are 18 years old or older - You have been diagnosed with a type of head and neck cancer called squamous cell carcinoma, affecting the lip, mouth, throat, or voice box - This is your first ever cancer diagnosis (you have not had cancer before) Who may not be able to join: -...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05328024 · Centre Paul Strauss Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 25 August 2029
🇫🇷 FR

Who might be able to join this trial: - People who have squamous cell carcinoma (a type of cancer) of the head and neck that has come back after previous treatment, cannot be treated with local therapies, and/or has spread to other parts of the body - People whose tumour can be directly examined by a doctor (such as ca...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05333523 · Radboud University Medical Center Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 December 2029
🇳🇱 NL

Who might be able to join this trial: - Adults aged 18 or older who have been newly diagnosed with a specific type of head and neck cancer (squamous cell carcinoma) affecting the oropharynx, larynx, or hypopharynx, at certain stages as defined by medical staging systems. - People whose cancer diagnosis has been confirm...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05340491 · Sun Yat-sen University Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with a local return of their cancer, with or without spread to nearby lymph nodes, at least 1 year after completing their original radical treatment - People whose cancer cannot be treated with surgery - People whose cancer has been confirmed b...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05342792 · Sun Yat-sen University Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 June 2027
🇨🇳 CN

**Who might be able to join this trial:** - People who were between 18 and 65 years old when they were diagnosed - People whose cancer has been confirmed by a laboratory test as a specific type of nasopharyngeal (back of the nose/throat) cancer called "non-keratinizing carcinoma" according to WHO guidelines - People w...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05343325 · Fifth Affiliated Hospital, Sun Yat-Sen University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 March 2024
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with a specific type of cancer called squamous cell carcinoma in the head and neck area (mouth, throat, voice box, or lower throat), confirmed by a tissue sample, that has not yet been treated and is at a certain stage of severity. - Surgeons have det...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05352321 · Sun Yat-sen University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2025
🇨🇳 CN

**Who might be able to join this trial:** - You have a good general level of physical fitness and are able to carry out normal daily activities with little or no limitation (confirm with trial site). - You have been diagnosed with a specific type of nasopharyngeal cancer (a cancer in the back of the nose/throat), conf...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05375266 · University of Erlangen-Nürnberg Medical School Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 March 2026
🇩🇪 DE

Who might be able to join this trial: - People who have recently been diagnosed with a type of cancer called squamous cell carcinoma in the mouth, throat, voice box, or nearby areas, at a specific stage of the disease (study group) - People who do not have cancer but are having ear, nose, or jaw/facial surgery for anot...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05406167 · RefleXion Medical Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 25 April 2026
🇺🇸 US

**Who might be able to join this trial:** - People who are able to understand and are willing to sign a consent form agreeing to participate in the study. - People who have been diagnosed with a cancer — whether localised, spread to nearby areas, or spread to other parts of the body — for whom radiation therapy has be...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05408845 · NRG Oncology Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 July 2028
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed (confirmed by laboratory testing of tissue or cell samples) with salivary gland cancer that has come back or spread, and whose cancer tests positive for a protein called HER2 (either at a high level called "HER2-positive" or a lower level calle...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05414032 · University Health Network, Toronto Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 September 2027
🇨🇦 CA

**Who might be able to join this trial:** - People aged 18 or older at the time of screening (or the legal age of consent in their country). - People who are willing and able to give written consent before any trial-related procedures begin, including any locally required privacy authorizations. - People with a genera...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05419089 · Icahn School of Medicine at Mount Sinai Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 June 2029
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with a specific type of throat cancer (oropharyngeal squamous cell carcinoma) that can be surgically removed, and whose tumour has tested positive for a protein called p16 through laboratory testing at an approved central lab. - People whose ca...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05420948 · University of Chicago Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2026
🇺🇸 US

**Who might be able to join this trial:** - People who have been clinically confirmed to have head and neck cancer that has either come back (recurrent) or spread to other parts of the body (metastatic). - People who have not previously received whole-body (systemic) treatments for their recurrent or metastatic cancer...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05442957 · Medical University of South Carolina Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 January 2027
🇺🇸 US

**Who might be able to join this trial:** - People who are over 18 years old at the time of signing the consent form - People who have been diagnosed with a type of cancer affecting the mouth, throat, voice box, nose or sinuses, salivary glands, or skin of the face or neck (confirmed by a lab test) - People who have h...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05446467 · Zhejiang Provincial People's Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 March 2026
🇨🇳 CN

Who might be able to join this trial: - Adults aged 18 to 85 years old - People with a laboratory-confirmed diagnosis of squamous cell carcinoma (a type of cancer) in the head and neck area, specifically at stage III or IVA, with no spread to distant parts of the body, and located in the oropharynx (HPV-negative only),...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05447169 · Sun Yat-sen University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2025
🇨🇳 CN

**Who might be able to join this trial:** - People who currently live in Southern China - People between the ages of 30 and 62 years old - People who are male - People who have at least one close blood relative (such as a parent, sibling, or child) who has been diagnosed with nasopharyngeal carcinoma (a type of throat...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05451004 · Canadian Cancer Trials Group Phase 3 · 2 countries Recruiting
Recruiting Phase 3 Est. completion 30 August 2030
🇨🇦 CA🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with cancer on one side of the throat (tonsil, base of tongue, soft palate, or throat wall) that does not cross or touch the middle of the throat. - Your cancer may be HPV-positive or HPV-negative. - Your cancer is at an early to intermediate stage wi...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05451303 · Viome Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇺🇸 US

"Who might be able to join this trial: - Adults aged 18 years or older. - People considered by their doctor to be at high risk of developing mouth or throat cancer. - People who have signed a consent form agreeing to take part in the trial. Who may not be able to join: - People who are pregnant. - People who are curre...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05491512 · Memorial Sloan Kettering Cancer Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 4 August 2027
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with HPV-related squamous cell cancer of the oropharynx (such as the tonsil, base of tongue, or oropharyngeal walls), confirmed by a tissue or cell sample from a biopsy or surgery - Cancer of unknown origin in the neck may also qualify, if a lymph nod...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05494190 · Eye & ENT Hospital of Fudan University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2027
🇨🇳 CN

**Who might be able to join this trial:** - People who are able to understand the study information and are willing to sign a consent form - People aged 18 to 75 years old - People of any gender - People who have a good level of physical functioning, as measured by a standard medical scoring tool called the Karnofsky...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05514275 · Zhejiang Cancer Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 August 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who have been newly diagnosed with a specific type of nasopharyngeal cancer (non-keratinizing type, confirmed by tissue biopsy according to World Health Organization classification) - People whose cancer has been staged as T3-4N1/N2-3, meaning the tumor is locally adv...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05517135 · National Cancer Centre, Singapore Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2027
🇸🇬 SG

**Who might be able to join this trial:** - People who are able to give written consent and are willing to follow the study schedule and requirements - People who are 21 years of age or older at the time of signing the consent form - People who fall into one of these three groups: (1) suspected nasopharyngeal cancer (...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05526924 · University of Chicago Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 January 2028
🇺🇸 US

**Who might be able to join this trial:** - People who have been clinically diagnosed with head and neck cancer that has come back and requires regional treatment. - People with oropharyngeal (throat) cancer whose tumour has been tested for HPV using a specific lab method (p16 IHC) and shown a positive result. - Peopl...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05527470 · Wei Jiang Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 11 November 2025
🇨🇳 CN

**Who might be able to join this trial:** - People who have been recently diagnosed with a specific type of nasopharyngeal (throat/nasal area) cancer confirmed by a tissue biopsy, classified as the non-keratinizing type according to World Health Organization guidelines - People whose cancer has been staged as Stage III...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05541016 · Mayo Clinic Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 August 2028
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 or older - People who have been diagnosed with, or are suspected to have, a type of cancer called squamous cell carcinoma that started in the back of the throat (oropharynx) - People whose treatment plan involves either surgery to remove the tumour through the...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05542706 · Centre Henri Becquerel Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 October 2026
🇫🇷 FR

**Who might be able to join this trial:** - People aged between 18 and 85 years old - People whose general health and ability to carry out daily activities meets a certain minimum level (known as ECOG score of 2 or below — confirm with trial site if unsure what this means) - People diagnosed with a specific type of can...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05544136 · Memorial Sloan Kettering Cancer Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 12 March 2027
🇺🇸 US

**Who might be able to join this trial:** - People who have a confirmed diagnosis of squamous cell carcinoma (a type of cancer) in the head and neck area — but not cancers starting in the nasopharynx, nasal cavity or sinuses, mouth, salivary glands, thyroid, or skin - People whose cancer's original location is unknown...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05547529 · Blokhin's Russian Cancer Research Center Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 14 September 2025
🇷🇺 RU

**Who might be able to join this trial:** - People who have given written consent to participate. - People who have been diagnosed with squamous cell carcinoma (a specific type of cancer) of the oesophagus (food pipe), confirmed by a tissue sample. - People whose cancer has been staged as cT1-4aN1-3M0, meaning the canc...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05562375 · Universidad Rey Juan Carlos Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2026
🇪🇸 ES

Who might be able to join this trial: - People who are older than 18 years of age. - People who have injuries in the lining of the mouth that are consistent with a condition called oral potentially malignant disorders (OPMD). - People who understand what the study involves and are able to give their agreement to take p...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05576974 · University of Texas Southwestern Medical Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2027
🇺🇸 US

**Who might be able to join this trial:** - Adults aged 18 or older - People with a biopsy-confirmed diagnosis of head and neck squamous cell carcinoma (a type of cancer affecting the head and neck region), either new or returning — or where the investigator has strong clinical suspicion of this diagnosis - For Part 1...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05582122 · UNICANCER Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 April 2028
🇫🇷 FR

**Who might be able to join this trial:** - People aged 18 years or older - People diagnosed with a type of throat cancer (oropharyngeal squamous cell carcinoma) that tests positive for a protein called p16 - People whose cancer is at a clinical stage of T1–T4, N0–N3, M0 (meaning stages I through III — not yet spread...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05582265 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 October 2028
🇨🇳 CN

**Who might be able to join this trial:** - People who have been confirmed through a biopsy to have a type of head and neck cancer (HNSCC) at stage III or IVA, where the plan is to treat it with the aim of curing it, including through surgery - People aged 18 to 79 years old at the time of joining the study - People w...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05587543 · Fudan University Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 1 October 2027
🇨🇳 CN

**Who might be able to join this trial:** - People who are willing and able to give written consent to participate - Adults aged 18 to 75 years old (any gender) - People with an expected survival of at least 3 months - People with a general health and activity level rated between 0 and 2 on a standard oncology scale (...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT05607888 · University Medical Centre Ljubljana Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2027
🇸🇮 SI

Who might be able to join this trial: - You have been diagnosed with cancer affecting the nasal passages, sinuses, and/or the base of the skull - Your disease in the nasal or sinus area has spread into or through the base of the skull - You are willing and able to give written consent to take part in the trial Who may...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05628922 · Fudan University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 July 2026
🇨🇳 CN

**Who might be able to join this trial:** - You are willing to sign a consent form and are able to follow all the study requirements, including scheduled visits and tests - You were between 18 and 70 years old when diagnosed - You have been newly diagnosed with a specific type of nasopharyngeal cancer (a cancer at the...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05635643 · Coherus Oncology, Inc. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 30 September 2026
🇺🇸 US

**Who might be able to join this trial:** **Criteria that apply to all parts of the trial (Arms 1a, 1b, 2, and 3):** - People who are 18 years of age or older. - People who have at least one tumour that can be measured using standard imaging guidelines. - People whose tumours that were previously treated with radiatio...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05644457 · Royal Marsden NHS Foundation Trust Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2026
🇬🇧 GB

Who might be able to join this trial: - You are 18 years of age or older - You have been diagnosed with head and neck cancer that has been confirmed by a tissue sample (biopsy), and the cancer has either come back, spread, or is at an advanced stage that cannot be cured - You are currently receiving immunotherapy (a ty...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05649865 · Region Skane Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2027
🇸🇪 SE

**Who might be able to join this trial:** - Your cancer (primary tumour) must be caused by HPV (human papillomavirus), a common virus that can lead to certain cancers - You must be 18 years of age or older - You must be able to understand and sign a consent form agreeing to take part in the trial - Your treatment must...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05658731 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2032
🇺🇸 US

Who might be able to join this trial: **Stratum A (currently receiving radiation treatment):** - You are between 1 and 25 years old - Your tumor is located in or near the brain, including areas such as the nasal cavity, sinuses, or eye socket - Your treatment plan includes radiation therapy (either proton or photon ty...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05668858 · Sichuan Baili Pharmaceutical Co., Ltd. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2026
🇨🇳 CN

Who might be able to join this trial: - People who are willing to voluntarily sign a consent form and follow the study requirements - People of any gender aged 18 to 75 years - People with a life expectancy of at least 3 months - People who have been confirmed by laboratory testing (tissue or cell samples) to have squa...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05674305 · Fudan University Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 January 2025
🇨🇳 CN

Who might be able to join this trial: - People who have been newly diagnosed with a specific type of nasopharyngeal cancer (a cancer at the back of the nose/throat), confirmed by tissue biopsy, classified as WHO type II or III (non-keratinizing type). - People aged between 18 and 70 years old. - People whose cancer is...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05674396 · M.D. Anderson Cancer Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 September 2027
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 or older - People who are willing to give their formal agreement to take part in the study - People whose cancer has been confirmed by laboratory testing to be squamous cell carcinoma (a specific type of cancer that develops from certain skin-like cells) - Peop...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05686226 · Christian Hinrichs Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 January 2027
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with metastatic or recurring/treatment-resistant cancer that has tested positive for the HPV-16 virus strain, confirmed through laboratory testing. - People whose tumor tissue and/or blood has been confirmed to carry the HPV-16 type through a c...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05707819 · Cancer Hospital of Guangxi Medical University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2023
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with a specific type of nasopharyngeal cancer (a non-keratinizing type, confirmed by tissue testing) - People whose cancer has been staged as Stage III or Stage IVA using a standard staging system (AJCC 8th edition, specific tumor and lymph nod...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05710679 · Centre Jean Perrin Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2029
🇫🇷 FR

**Who might be able to join this trial:** - People aged 18 to 80 years old - People who have been diagnosed with squamous cell carcinoma (a type of cancer) that has been confirmed by a tissue biopsy and has spread to nearby lymph nodes, and who have not yet received any treatment for it - People whose cancer is locate...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05727761 · University of Minnesota Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 28 July 2026
🇺🇸 US

**Who might be able to join this trial:** - People who have had a biopsy confirming abnormal tissue growth (hyperplasia) in high-risk mouth areas such as the floor of the mouth, the movable part of the tongue, or the throat, OR any level of abnormal cell changes (dysplasia or hyperplasia) in a red patch (erythroplakia...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05738603 · Jakub Szrama Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 September 2026
🇵🇱 PL

Who might be able to join this trial: - People who have been approved by their medical team to have a specific type of reconstructive surgery for the head and neck area (called free flap surgery). - People who are willing and able to provide written agreement to take part in the trial. Who may not be able to join: - P...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05740033 · University of British Columbia Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2025
🇨🇦 CA

Who might be able to join this trial: - Adults aged 18 years or older - People with a condition affecting the mouth (whether cancerous or non-cancerous) that requires a type of reconstructive surgery using tissue taken from the forearm Who may not be able to join: - People with serious health conditions, including can...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05747625 · Eben Rosenthal Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 28 February 2027
🇺🇸 US

Who might be able to join this trial: - People aged 19 years or older - People who have been diagnosed with squamous cell carcinoma (a type of cancer) of the head and neck, confirmed by a biopsy - People with head and neck cancer at any stage and in any location within the head and neck area, including those whose canc...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05757817 · Institut Claudius Regaud Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2026
🇫🇷 FR

**Who might be able to join this trial:** - People who have been diagnosed with squamous cell carcinoma (a type of cancer) of the mouth or throat, confirmed by a tissue biopsy - People whose cancer is at a specific stage — it has not spread to distant parts of the body, and falls within a defined range of tumor and ly...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05758389 · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medic... Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 7 August 2025
🇨🇳 CN

**Who might be able to join this trial:** - People aged between 18 and 75 years old - People who have been confirmed by tissue or cell testing to have squamous cell carcinoma of the head and neck, including cancers of the mouth, throat (oropharynx or hypopharynx), or voice box (larynx) - People who have at least one t...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05772208 · Fudan University Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 January 2025
🇨🇳 CN

**Who might be able to join this trial:** - You have been newly diagnosed with a specific type of nose and throat cancer (nasopharyngeal carcinoma, WHO type II or III) confirmed by a tissue biopsy, and your cancer tests positive for a protein called EGFR. - You are between 18 and 70 years old. - Your cancer is at an ad...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05774483 · Tata Memorial Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2032
🇮🇳 IN

**Who might be able to join this trial:** - People who are older than 18 years of age - People who have been confirmed by biopsy to have invasive squamous cell carcinoma (a type of cancer) located on the tongue or the inner cheek lining (buccal mucosa) - People whose tumour is classified as T1 or T2 in size, according...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05777824 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 December 2025
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 75 years old, of any gender - People who have been confirmed through a tissue sample (biopsy) to have squamous cell carcinoma of the head and neck - People whose cancer is locally advanced, meaning it has grown significantly into nearby tissue or spread to n...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05784688 · TiumBio Co., Ltd. Phase 2 · 2 countries Recruiting
Recruiting Phase 2 Est. completion 1 December 2026
🇰🇷 KR🇺🇸 US

**Who might be able to join this trial:** - Adults aged 18 or older - People whose doctor estimates they have a life expectancy of at least 12 weeks - People whose cancer can be measured on scans, according to standard medical criteria (RECIST v1.1) - People who are fully active or have only minor limitations in daily...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05793151 · Medical University of South Carolina Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 March 2028
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 or older - People diagnosed with a type of cancer called squamous cell carcinoma (or a closely related type) affecting the mouth, throat, voice box, nasal area, or sinuses — or where the original source of the cancer is unknown - People whose cancer has been a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05798793 · Hospital of Stomatology, Wuhan University Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 July 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with oral squamous cell carcinoma (a type of mouth cancer) confirmed by a tissue biopsy. - People whose cancer is locally advanced (has grown or spread to nearby lymph nodes but not to distant parts of the body) and where a surgeon at Wuhan Uni...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05799144 · Michael K. Gibson Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 September 2027
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 or older who have given signed, dated written consent to participate - People with a cancer of the back of the throat (oropharynx) that has come back or spread, where the tumor tests positive for a protein called p16 (linked to HPV) and also tests positive for...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05800574 · Fox Chase Cancer Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 23 September 2026
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with squamous cell carcinoma (a type of cancer) of the oropharynx (the middle part of the throat, including the back of the mouth and base of tongue), confirmed by a tissue test - People whose treatment plan requires radiation to both sides of...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05815927 · European Organisation for Research and Treatment of Cancer - EORTC Phase 3 · 4 countries Recruiting
Recruiting Phase 3 Est. completion 15 July 2027
🇧🇪 BE🇮🇹 IT🇪🇸 ES🇨🇭 CH

**Who might be able to join this trial:** - People who are 18 years of age or older at the time of signing the consent form - People who have a laboratory-confirmed diagnosis of squamous cell carcinoma of the head and neck, specifically affecting the mouth, throat (oropharynx), hypopharynx, voice box (larynx), or an u...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05817617 · Centro di Riferimento Oncologico - Aviano Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2024
🇮🇹 IT

Who might be able to join this trial: - People who have been diagnosed with head and neck squamous cell cancer (a type of cancer affecting areas such as the mouth, throat, or related areas), confirmed by a tissue sample test - People whose cancer has not spread to distant parts of the body and is at a locally advanced...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05837221 · University of Colorado, Denver Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2026
🇺🇸 US

Who might be able to join this trial: - People who are 18 years of age or older - People who are being seen and assessed by a doctor at the adult Ear, Nose, and Throat (ENT) clinic at the University of Colorado Health - People who have been diagnosed with oral squamous cell carcinoma (a type of mouth cancer) — OR — peo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05838729 · Coordination Pharmaceuticals, Inc. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 September 2026
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with head and neck cancer that requires palliative radiotherapy (radiation treatment aimed at relieving symptoms rather than curing the disease) - People with head and neck squamous cell cancer that cannot be surgically removed, has come back,...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05853692 · Catholic University of the Sacred Heart Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 10 October 2027
🇮🇹 IT

**Who might be able to join this trial:** - People diagnosed with head and neck cancer affecting the oral cavity (mouth), pharynx (throat), salivary glands, or an unknown primary site, who are receiving radiation therapy to the area as a curative (main) treatment - People with the same types of head and neck cancer who...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05854823 · Fifth Affiliated Hospital, Sun Yat-Sen University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 9 April 2027
🇨🇳 CN

**Who might be able to join this trial:** - People diagnosed with a specific type of head and neck cancer (squamous cell carcinoma) affecting the mouth, throat, voice box, or nearby areas, at a certain stage of advancement, who have already received pre-surgery treatment and then had surgery to remove the cancer — all...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05854849 · Sun Yat-sen University Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 December 2025
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 70 years old, of any gender. - People who have been diagnosed through a tissue test with a specific type of nasopharyngeal cancer (NPC) that has come back or spread, and where the cancer cannot be treated with local treatments alone. - People who have not y...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05872880 · Xiangya Hospital of Central South University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2026
🇨🇳 CN

**Who might be able to join this trial:** - People with a general health and activity level rated as fully active or restricted only in strenuous physical activity (as measured by a standard oncology performance scale). - People newly diagnosed with squamous cell carcinoma (a specific type of cancer) of the mouth lini...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05877872 · Sun Yat-sen University Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 30 March 2029
🇨🇳 CN

**Who might be able to join this trial:** - Your nasopharyngeal cancer (cancer in the back of the nose/throat) came back more than 6 months after you finished radiation therapy. - A tissue sample (biopsy) has confirmed that your nasopharyngeal cancer has returned. - Your returned cancer is considered removable by surg...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05889091 · Memorial Sloan Kettering Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 16 May 2027
🇺🇸 US

Who might be able to join this trial: - You must be 18 years of age or older - You have been diagnosed with a type of head and neck cancer affecting areas such as the throat, voice box, or surrounding regions - Your main treatment for this cancer was radiation therapy, with or without chemotherapy - After that treatmen...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05892354 · First Affiliated Hospital of Guangxi Medical University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 April 2025
🇨🇳 CN

**Who might be able to join this trial:** - You have a relatively good level of physical fitness and are able to carry out normal daily activities (confirm with trial site) - You are between 18 and 70 years old, and are male or a woman who is not pregnant - You have been confirmed by a tissue biopsy to have a specific...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05894083 · University of Michigan Rogel Cancer Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2026
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with squamous cell carcinoma of the oropharynx (such as the tonsil, base of tongue, throat wall, or soft palate) or an unknown primary cancer site, confirmed by biopsy or cell testing, and shown to be p16 positive or HPV positive by lab testing...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05901545 · Vanderbilt-Ingram Cancer Center Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 30 November 2028
🇺🇸 US

**Who might be able to join this trial:** - People aged 19 years or older - People who have been diagnosed with squamous cell carcinoma (a type of cancer) of the head and neck, confirmed by a biopsy, where the lymph nodes either show no signs of cancer or are considered suspicious - People with any stage of head and ne...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05913388 · Providence Health & Services Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 February 2028
🇺🇸 US

**Who might be able to join this trial:** - People diagnosed with melanoma that cannot be surgically removed or has spread to other parts of the body, including cases where the original source of the melanoma is unknown, or where it started in the mucous membranes. Diagnosis must have been confirmed through a previous...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05919290 · University Health Network, Toronto Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2029
🇨🇦 CA

**Who might be able to join this trial:** **For people with cancer:** - Adults aged 18 years or older - People who have been diagnosed with a specific type of head and neck cancer called squamous cell carcinoma, confirmed through a tissue test - People whose cancer (in the primary area or nearby lymph nodes) measures...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05933889 · Royal Marsden NHS Foundation Trust Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2027
🇬🇧 GB

**Who might be able to join this trial:** - People aged 18 years or older - People whose primary cancer is located in the oropharynx (which includes the tonsil, soft palate, base of the tongue, and the side and back walls of the throat) - People whose cancer has been confirmed by laboratory testing to be squamous cell...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05941741 · Sun Yat-sen University Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 December 2027
🇨🇳 CN

**Who might be able to join this trial:** - People who have recently been diagnosed with a specific type of nasopharyngeal carcinoma (a cancer at the back of the nose/throat) confirmed by tissue biopsy — specifically the non-keratinizing type (classified as WHO Type II or III) - People of any gender between 18 and 70...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05952934 · University of Arkansas Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 July 2031
🇺🇸 US

Who might be able to join this trial: - People who are able to give informed consent to participate - People who are 18 years of age or older, male or female - People who have been diagnosed with squamous cell carcinoma (a type of cancer) of the head and neck, and who have completed curative treatment — such as surgery...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05973656 · Masonic Cancer Center, University of Minnesota Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 November 2026
🇺🇸 US

**Who might be able to join this trial:** - You are between 21 and 45 years old and occasionally drink alcohol (at least 1 drink per month), OR between 18 and 45 years old and have not had any alcohol in the last 6 months - You drink at least 1 alcoholic drink per month (for most volunteers) or have had at least 1 dri...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05977907 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 16 October 2026
🇺🇸 US

**Who might be able to join this trial:** - People who are willing and able to sign a written consent form agreeing to take part in the trial - People who are 18 years of age or older at the time of signing the consent form - People who have been diagnosed with a non-bulky squamous cell carcinoma (a type of cancer) of...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05980702 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 3 April 2025
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 65 years old - People who have been diagnosed with head and neck squamous cell carcinoma (a type of cancer affecting the head and neck region) confirmed by laboratory testing, at a stage classified as T3 or T4, N0, and considered operable by surgery - Peopl...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05980715 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 31 December 2030
🇨🇳 CN

**Who might be able to join this trial:** - People diagnosed with locally advanced head and neck squamous cell carcinoma (a specific type of head and neck cancer) at certain stages, who had standard surgery after pre-surgery treatment combining immunotherapy and chemotherapy, and whose pathology results showed no rema...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05988060 · Institute Verbeeten Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 9 November 2025
🇳🇱 NL

Who might be able to join this trial: - People who have head and neck cancer and are scheduled to receive radiation therapy, with or without chemotherapy or targeted therapy - People who are 18 years of age or older - People who can read and write in Dutch well enough to participate - People who have a reasonable level...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05994170 · Zhongshan People's Hospital, Guangdong, China Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 4 August 2026
🇨🇳 CN

Who might be able to join this trial: - People who have been confirmed by biopsy to have a specific type of nasopharyngeal (throat/nose area) cancer called nonkeratinizing nasopharyngeal carcinoma (WHO types II or III). - People who have been newly diagnosed with this cancer at stage I through IVa, based on a standard...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05995821 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 25 August 2026
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with, or are suspected of having, a cancer of the upper airways or digestive tract, and who may be receiving treatments that could affect the immune system - People who are able to understand the study information and are willing to sign a consent f...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05996432 · Vanderbilt-Ingram Cancer Center Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 30 November 2026
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with head and neck squamous cell carcinoma (a type of cancer in the head or neck area) confirmed by a tissue or cell sample, or who have a clinical diagnosis of brain metastases (cancer that has spread to the brain). - People who have at least one t...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT06006169 · Sichuan Baili Pharmaceutical Co., Ltd. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who have voluntarily agreed to take part and have signed a consent form - Adults aged 18 to 75 years (male or female) - People whose doctors estimate they are likely to live for at least 3 more months - People who are fairly active and able to care for themselves, wit...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06007092 · Gustave Roussy, Cancer Campus, Grand Paris Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 November 2025
🇫🇷 FR

**Who might be able to join this trial:** - People aged 18 or older, of any gender. - People who are able and willing to attend scheduled visits, follow the treatment plan, and complete required tests throughout the study. - People who have been diagnosed with a specific type of throat cancer called oropharyngeal squa...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06007729 · Hansoh BioMedical R&D Company Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 12 December 2025
🇨🇳 CN

Who might be able to join this trial: - People who are at least 18 years old at the time of screening. - People who have a confirmed diagnosis of recurring or metastatic head and neck squamous cell carcinoma (HNSCC), or another type of solid tumour, and whose cancer has gotten worse on standard treatments or who were u...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06016920 · Nykode Therapeutics ASA Phase 2 · 8 countries Recruiting
Recruiting Phase 2 Est. completion 1 September 2027
🇨🇿 CZ🇫🇷 FR🇩🇪 DE🇭🇺 HU🇳🇴 NO🇵🇱 PL🇪🇸 ES🇬🇧 GB

**Who might be able to join this trial:** - People aged 18 or older (or the legal age of consent in their country, whichever is higher) at the time of signing the consent form - People with a confirmed diagnosis of head and neck cancer (specifically in the oropharynx — the middle part of the throat) that has returned...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06019130 · German Society for Pediatric Oncology and Hematology GPOH gGmbH Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 9 January 2026
🇩🇪 DE

Who might be able to join this trial: - Children and teenagers aged 3 to 17 years with a newly confirmed diagnosis of nasopharyngeal carcinoma (a type of cancer at the back of the nose/throat), as classified by current international standards, OR adults aged 18 and over with a newly confirmed diagnosis of nasopharyngea...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06026878 · Air Force Military Medical University, China Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 30 September 2025
🇨🇳 CN

**Who might be able to join this trial:** - You are between 18 and 75 years old. - You have been diagnosed with a specific type of nasopharyngeal cancer (a cancer at the back of the nose/throat), confirmed by a lab test, at an advanced stage (stage III to IVB). - Your doctors have determined that you are suitable for...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06030011 · The University of Texas Health Science Center, Houston Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 August 2028
🇺🇸 US

Who might be able to join this trial: **For patients:** - People who have been diagnosed with head and neck cancer (confirmed by a tissue sample/biopsy) and are receiving radiation treatment, with or without chemotherapy, with the goal of curing the cancer - People who speak English or Spanish **For clinicians (healt...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06030440 · University of Erlangen-Nürnberg Medical School Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 December 2031
🇩🇪 DE

**Who might be able to join this trial:** - You have been diagnosed with a specific type of cancer (squamous cell carcinoma) affecting the mouth, voice box, or throat area, confirmed by a tissue sample — with some exceptions for very early voice box cancers (confirm with trial site) - You have already had surgery to r...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06039631 · Fudan University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 September 2027
🇨🇳 CN

**Who might be able to join this trial:** - People who have given written consent and are willing to follow the study plan. - People aged 18 to 75 years old. - People whose cancer has been confirmed by a tissue biopsy to be squamous cell carcinoma of the larynx (voice box) or hypopharynx (lower throat). - People with...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06047236 · University of Erlangen-Nürnberg Medical School Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 September 2029
🇩🇪 DE

**Who might be able to join this trial:** *People in the main observation group:* - People who have recently been diagnosed with a cancerous tumour of a salivary gland in the head and neck area (not including squamous cell carcinoma) - The tumour must be large enough that a tissue sample can be taken from its centre w...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06052839 · Dan Zandberg Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2026
🇺🇸 US

**Who might be able to join this trial:** - You have squamous cell carcinoma (a type of cancer) in the head and neck area that has come back or spread, and cannot be cured with local treatments like surgery or radiation. - Your tumor has tested positive for a protein called PD-L1, with a score greater than 1 (this is...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06055257 · Sunnybrook Health Sciences Centre Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 December 2027
🇨🇦 CA

**Who might be able to join this trial:** - People who have been diagnosed with a bone condition called osteonecrosis of the jaw (ORN) following completion of radiation therapy, where there is an exposed, damaged area of jaw bone larger than 20 mm² - People who a Hyperbaric (high-pressure oxygen) specialist doctor has...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06055816 · Zhejiang Cancer Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 September 2024
🇨🇳 CN

**Who might be able to join this trial:** - You are 65 years of age or older and have recently been diagnosed with nasopharyngeal cancer (a type of cancer in the back of the nose/throat), confirmed by a medical test - You are generally able to carry out daily activities and care for yourself, as assessed by your doctor...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06059261 · Chongqing University Cancer Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 February 2027
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 65 years, either male or female (not pregnant), with a general health score showing they are fully active or have only minor restrictions in physical activity (ECOG score 0–1) - People whose cancer has been confirmed by a laboratory test to be a specific ty...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06061705 · Fondation Hôpital Saint-Joseph Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 29 December 2025
🇫🇷 FR

Who might be able to join this trial: - Adults aged 18 or older - People who have been diagnosed with a specific type of head and neck cancer (called CEVADS) affecting the mouth, throat, voice box, or the area around the voice box, confirmed through a tissue sample test - People whose cancer has come back for the first...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06064097 · National Cancer Institute (NCI) Phase 2 · 4 countries Recruiting
Recruiting Phase 2 Est. completion 31 December 2026
🇨🇦 CA🇳🇿 NZ Puerto Rico🇺🇸 US

**Who might be able to join this trial:** - People aged 21 or younger at the time of joining the trial. - People newly diagnosed with stage II, III, or IV nasopharyngeal carcinoma (a type of cancer in the back of the nose and throat), confirmed by a tissue biopsy at the time of original diagnosis. - People whose abili...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06077643 · Assistance Publique - Hôpitaux de Paris Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 10 June 2026
🇫🇷 FR

**Who might be able to join this trial:** - You have had your voice box (larynx) fully removed at Bichat Hospital or HEGP within the last four years - You have finished all treatments related to the condition that led to your voice box being removed - You are able to travel to Bichat Hospital to attend all four session...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06080503 · University of Texas Southwestern Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2028
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed through laboratory testing with a specific type of throat cancer (squamous cell carcinoma or a related variant) located in the voice box (glottis). - People whose cancer is classified as stage 0, I, or II (meaning it has not spread beyond the v...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06085781 · University Health Network, Toronto Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 January 2027
🇨🇦 CA

**Who might be able to join this trial:** - People aged 18 or older - People who have been diagnosed with head and neck squamous cell carcinoma (a type of cancer affecting the head and neck area), confirmed through a tissue sample test - People whose cancer (either the main tumour or affected lymph nodes) is larger th...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06087614 · Rajiv Gandhi Cancer Institute & Research Center, India Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 April 2028
🇮🇳 IN

Who might be able to join this trial: - People aged between 18 and 70 years old - People who are willing to give their agreement to take part by signing or video-recording a consent form - People who are well enough to carry out daily activities with little or no limitation (as assessed by a doctor using a standard sca...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06092957 · Sun Yat-sen University Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 30 October 2029
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with a specific type of nasopharyngeal cancer (a non-keratinizing cancer of the back of the nose/throat, known as WHO type II or III) confirmed by a tissue sample. - People whose cancer has been staged as stage III or IVA (using a standard stag...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06093061 · National Cancer Centre, Singapore Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 October 2028
🇸🇬 SG

**Who might be able to join this trial:** - People who are able to give written consent and are willing to follow the study schedule and requirements - People who are 21 years of age or older at the time of signing the consent form - People diagnosed with locally advanced nasopharyngeal cancer (a type of cancer at the...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06096038 · UNC Lineberger Comprehensive Cancer Center Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 September 2026
🇺🇸 US

Who might be able to join this trial: - You must be willing and able to sign a consent form agreeing to take part in the study. - You must be 18 years old or older at the time you sign the consent form. - You must be reasonably able to carry out daily activities, as measured by a standard health scoring system (a score...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06097468 · University of California, San Francisco Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 March 2028
🇺🇸 US

**Who might be able to join this trial:** - People who are suspected to have a type of mouth cancer called oral cavity squamous cell carcinoma (OSCC), and who are planning to have a diagnostic biopsy to confirm the diagnosis — confirmation of cancer from that biopsy is required before a person can formally enrol. - Pe...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06100497 · Beijing Tongren Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 October 2025
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with advanced (stage III to IVB) poorly differentiated head and neck cancer — specifically cancer of the hypopharynx, larynx, oropharynx, or nasal cavity and sinuses (nasopharyngeal cancer is not included) — confirmed by a tissue or cell sample...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06102395 · Beijing Tongren Hospital Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 30 April 2027
🇨🇳 CN

**Who might be able to join this trial:** - People diagnosed with stage IIIA to IVB head and neck squamous cell carcinoma (a type of head and neck cancer), confirmed by laboratory testing of tissue or cell samples - People who have not previously received immunotherapy treatment - People the research team believes can...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06103669 · University of California, Davis Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2033
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with one of the following cancer types, confirmed by lab testing: breast cancer, gynecological cancer, head and neck cancer, sarcoma, or another solid tumor cancer specified by the study. - You are willing and able to sign a consent form agreeing to t...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06107686 · MediLink Therapeutics (Suzhou) Co., Ltd. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 November 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who have been fully informed about the trial and have willingly signed and dated a consent form before the trial begins - People aged between 18 and 75 years (inclusive) - People who have a confirmed diagnosis (through tissue or cell testing) of non-small cell lung ca...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06108089 · University of Utah Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2025
🇺🇸 US

Who might be able to join this trial: - People who have been newly diagnosed with a type of head and neck cancer called squamous cell carcinoma, confirmed by a tissue sample or needle test, where the cancer started in the mouth, voice box, throat, back of the nasal passage, or back of the throat. - People whose treatme...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06109207 · West China Hospital Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 31 October 2024
🇨🇳 CN

**Who might be able to join this trial:** - You are 18 years old or older. - You have been diagnosed with a type of head and neck cancer (called HNSCC) confirmed by a lab test — but not nasopharyngeal carcinoma (a specific type of throat cancer). - Your cancer has been newly diagnosed and has not spread to other parts...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06125743 · Abramson Cancer Center at Penn Medicine Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 August 2026
🇺🇸 US

**Who might be able to join this trial:** - You are older than 18 years of age - You have already completed your main treatment for head and neck cancer - Your cancer is no longer detected (you have been told there is no sign of cancer) - You have already finished an initial course of therapy for swelling (lymphedema)...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06127784 · Western University, Canada Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2026
🇨🇦 CA

Who might be able to join this trial: - People aged 18 years or older - People who are willing to give their formal consent to participate - People who have been diagnosed with stage I to IVA head and neck mucosal cancer (in areas such as the voice box, throat, mouth, or nasal passages) - People whose last major cancer...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06129864 · AstraZeneca Phase 3 · 23 countries Recruiting
Recruiting Phase 3 Est. completion 17 April 2030
🇦🇹 AT🇧🇪 BE🇧🇷 BR🇨🇦 CA🇨🇳 CN🇫🇷 FR🇩🇪 DE🇭🇺 HU +15 more

**Who might be able to join this trial:** - People who have been diagnosed with locally advanced squamous cell carcinoma (a specific type of cancer) in one of these areas: the oropharynx (back of the throat), hypopharynx (lower throat), oral cavity (mouth), or larynx (voice box), confirmed by a tissue or cell sample....

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06137274 · H. Lee Moffitt Cancer Center and Research Institute Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 May 2027
🇺🇸 US

Who might be able to join this trial: - People who are willing and able to sign and date a consent form for the study - People who are willing to follow all study procedures and are available for the full duration of the study - People who have a good general health status, able to carry out normal daily activities wit...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06137378 · University of Leipzig Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2028
🇩🇪 DE

**Who might be able to join this trial:** - Adults aged 18 or older who have been confirmed through a tissue test to have squamous cell carcinoma (a type of cancer) of the larynx (voice box) or hypopharynx (lower throat), and whose medical team has decided that full surgical removal of the larynx is appropriate. - Peo...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06145308 · Peking Union Medical College Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 10 July 2028
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with salivary gland cancer, confirmed through a tissue sample tested in a lab - Your tumor tissue has been tested for certain proteins (HER2, NTRK, AR, and TROP-2) - You are generally well enough to carry out everyday activities with little or no limi...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06148077 · Universidad de La Frontera Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2025
🇨🇱 CL

Who might be able to join this trial: - People who have been diagnosed with head and neck cancer - People who are 18 years of age or older - People who have had surgery and/or radiotherapy (radiation treatment) for head and neck cancer - People who finished their cancer treatment between 3 and 36 months before joining...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06161779 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 16 February 2028
🇨🇳 CN

Who might be able to join this trial: - People diagnosed with a specific stage of throat cancer (called hypopharyngeal squamous cell carcinoma, at stage T2 or T3) located in particular areas of the lower throat known as the piriform sinus or the back wall of the hypopharynx. - People where the opposite side of the voic...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06163534 · Tempus AI Not Applicable · 2 countries Recruiting
Recruiting Not Applicable Est. completion 1 March 2028
Puerto Rico🇺🇸 US

Who might be able to join this trial: - You must be 18 years of age or older - You must be willing and able to give your consent to participate in the trial - You must have been diagnosed (confirmed through a lab test of tissue or cells) with head and neck squamous cell cancer that has spread to other parts of the body...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06170021 · Sun Yat-sen University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 6 December 2025
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 70, of any sex - People with a good general health and activity level, as measured by a standard oncology scoring system called ECOG, with a score of 0 or 1 (meaning able to carry out normal daily activities with little or no restriction) - People who are w...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06170710 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 November 2025
🇨🇳 CN

Who might be able to join this trial: - People who have been diagnosed with squamous cell carcinoma (a type of cancer) in the head and neck area, including the mouth, throat, voice box, or the area connecting the throat to the oesophagus, confirmed through a tissue sample test. - People whose cancer has one or more hig...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06174428 · Viome Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇺🇸 US

Who might be able to join this trial: - You must be willing and able to sign and date a consent form before any study procedures take place - You must be willing and able to follow the study instructions as described in the recruitment letter - You must be 18 years old or older - A doctor must have examined you and sus...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06177301 · Fudan University Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - Your nasopharyngeal carcinoma (a type of head and neck cancer) has come back or spread, confirmed by a tissue or cell test - You have not previously received systemic (whole-body) treatment for the recurrent or spread cancer — though if you had chemotherapy before, you may s...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06182657 · Jiangxi Provincial Cancer Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2027
🇨🇳 CN

**Who might be able to join this trial:** - You are able to give your consent to take part in the study - You are over 18 years old - You are generally well enough to carry out daily activities with little or no limitation (this is measured using a standard scale — confirm with trial site) - Your cancer has been confir...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06184880 · Centre Hospitalier de Valence Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2029
🇫🇷 FR

Who might be able to join this trial: - People aged 18 years or older - People who have been recently diagnosed with a cancer of the upper throat, mouth, or airway area (confirmed by a tissue biopsy), where the cancer has not spread to other parts of the body - People with a life expectancy of at least 18 months - Peop...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06197776 · Sun Yat-sen University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇨🇳 CN

Who might be able to join this trial: - People who have nasopharyngeal carcinoma (a type of cancer in the back of the nose and throat) that has come back or spread to other parts of the body - People of any gender between 18 and 70 years old - People who are well enough to carry out daily activities with little or no l...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06208826 · Tianjin Medical University Cancer Institute and Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 September 2027
🇨🇳 CN

Who might be able to join this trial: - People who are able to understand the study and are willing to give their informed consent to participate. - People aged between 18 and 80 years old, either male or female. - People who are generally able to carry out everyday activities with no or minimal limitations, as measure...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06216171 · University Hospital, Essen Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 April 2025
🇩🇪 DE

Who might be able to join this trial: - You are generally healthy and able to carry out daily activities with little to no limitation (confirm with trial site) - You have not received any previous treatment for cancer Who may not be able to join: - You have significant limitations in your ability to carry out daily ac...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06219980 · Sun Yat-sen University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 7 December 2025
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with squamous cell cancer (a specific type of cancer) of the mouth or throat, confirmed by a laboratory test - People whose cancer is at stage III or IVa, based on a specific cancer staging system (the 8th edition of the AJCC staging guide) - Pe...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06223568 · National Cancer Institute (NCI) Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 10 January 2028
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with a specific type of throat cancer (oropharyngeal squamous cell carcinoma) at an early stage (Stage I or II), confirmed by a tissue or cell sample from either the main tumour or a nearby lymph node, and where surgery to remove the cancer is...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06228079 · Eye & ENT Hospital of Fudan University Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 30 June 2028
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with nasopharyngeal carcinoma (a type of cancer in the back of the nose/throat) that has come back after previous treatment - People whose cancer is at a specific, earlier stage of recurrence, based on how far it has spread in the local area (c...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06235203 · Eye & ENT Hospital of Fudan University Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 30 June 2027
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with nasopharyngeal carcinoma (a type of cancer in the back of the nose and throat) that has come back after previous treatment. - People whose cancer has come back at a specific stage — either growing into certain nearby structures or reaching...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06236464 · National Cancer Institute, Naples Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 19 November 2025
🇮🇹 IT

**Who might be able to join this trial:** - You are 18 years old or older - You have been diagnosed with squamous cell carcinoma (a type of cancer) affecting one of these areas: the anus, cervix (neck of the womb), vulva, or head and neck region — including early-stage or more advanced forms - You are being considered...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06239220 · Glenn J. Hanna Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 July 2026
🇺🇸 US

**Who might be able to join this trial:** - People who have already been diagnosed with a confirmed type of head and neck cancer called squamous cell carcinoma (HNSCC), where the cancer has come back, spread to other parts of the body, or cannot be removed by surgery or cured. This includes cancers starting in the mou...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06248996 · Lund University Hospital Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 4 March 2028
🇸🇪 SE

**Who might be able to join this trial:** - People who are at least 18 years old. - People who have been diagnosed (confirmed by tissue or cell testing) with a specific type of head and neck cancer — in the throat (oropharynx), lower throat (hypopharynx), voice box (larynx), or mouth — that has not been treated before...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06258811 · Lai-ping Zhong Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 30 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who are generally well enough to carry out daily activities with little to no limitation (measured by a standard medical scale called ECOG, scoring 0 or 1) - People who have been diagnosed with squamous cell carcinoma (a type of cancer) in the mouth, including the ton...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06259552 · SparX Biotech(Jiangsu) Co., Ltd. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 September 2027
🇺🇸 US

**Who might be able to join this trial:** - Adults aged 18 or older who can understand the study, are not incarcerated, are willing to sign a consent form, and can attend scheduled visits and follow study requirements - People who have a solid tumour cancer (confirmed by laboratory testing of tissue or cells) that has...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06259721 · Jiangxi Provincial Cancer Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 9 February 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who have been confirmed (through tissue or cell testing) to have nasopharyngeal carcinoma (a type of cancer affecting the back of the nose and throat) that has come back or spread, and cannot be cured with surgery or radiation therapy. People diagnosed based on imagin...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06277050 · Jiangxi Provincial Cancer Hospital Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 20 February 2030
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with nasopharyngeal carcinoma (a type of cancer in the back of the nose/throat) confirmed by a lab test. - Your cancer is considered "high-risk," meaning it meets at least one of these conditions: the cancer has spread to distant lymph nodes (but not...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06287034 · Regina Elena Cancer Institute Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 21 March 2025
🇮🇹 IT

**Who might be able to join this trial:** - People who have been diagnosed (confirmed by tissue testing) with squamous cell carcinoma (a type of cancer) of the voice box (larynx) that has come back or not fully responded to treatment, where the original treatment was radiation therapy alone or radiation therapy combin...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06289049 · University of Alberta Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 June 2026
🇨🇦 CA

Who might be able to join this trial: - Adults aged 18 or older of any gender - People who have had any type or stage of head and neck cancer, regardless of what treatment they received - People who are at least one year past the end of their cancer treatment and have a certain minimum level of shoulder movement (the t...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06291610 · University of Aarhus Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2025
🇩🇰 DK

Who might be able to join this trial: - You have been diagnosed with cancer of the pharynx (throat) or larynx (voice box) - You have received spoken information about the DAHANCA 35 study - You have read the patient information booklet provided by DAHANCA 35 - You are 18 years of age or older - You are able to speak an...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06297902 · Oslo University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2027
🇳🇴 NO

Who might be able to join this trial: - People who have been diagnosed with a confirmed invasive squamous cell carcinoma (a type of cancer) in the head and neck area, specifically in locations including the sinonasal area, oral cavity, hypopharynx, larynx, HPV-negative oropharyngeal region, or advanced HPV-positive oro...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06301165 · Sun Yat-sen University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2024
🇨🇳 CN

**Who might be able to join this trial:** - You are between 18 and 65 years old - Your cancer has been confirmed by a tissue sample as a specific type of nasopharyngeal carcinoma (a cancer in the back of the nose/throat), classified as WHO type II or III - Your cancer has been staged at a locally advanced level with no...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06305676 · H. Lee Moffitt Cancer Center and Research Institute Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2029
🇺🇸 US

**Who might be able to join this trial:** - You are at least 18 years old - You have been recently diagnosed with a specific type of throat/mouth cancer (squamous cell carcinoma of the oropharynx, stages I through IV), confirmed by a tissue sample test - You have not received any treatment for this cancer (such as sur...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06307314 · Nanfang Hospital, Southern Medical University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇨🇳 CN

Who might be able to join this trial: - People who are over 18 years of age - People who are willing to voluntarily sign a consent form to take part - People who have been diagnosed with nasopharyngeal carcinoma (a type of cancer at the back of the nose) or a head and neck tumour - People whose treatment plan includes...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06307327 · Nanfang Hospital, Southern Medical University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who are willing to voluntarily sign a consent form agreeing to take part in the trial - People who are 18 years of age or older at the time of signing the consent form - People who have been diagnosed with a head and neck tumour (confirmed through laboratory testing of...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06307418 · Uppsala University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 October 2026
🇸🇪 SE

Who might be able to join this trial: - People who are an informal caregiver (such as a family member or close friend) for someone with head and neck cancer, where that patient has agreed to allow their caregiver to be contacted about the trial. - People who are caring for a patient who is about to start radiation ther...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06308328 · Nanfang Hospital, Southern Medical University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 November 2026
🇨🇳 CN

Who might be able to join this trial: - People who are willing and able to provide written consent to participate. - People who are 18 years of age or older. - People who have been diagnosed with nasopharyngeal carcinoma (a type of cancer in the back of the nose and throat) confirmed by tissue testing, and who are curr...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06309225 · Omar Mahmoud Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 September 2026
🇺🇸 US

**Who might be able to join this trial:** - People who have been confirmed by a pathology test to have squamous cell carcinoma (a type of cancer) located in the oropharynx — this includes the tonsils, base of the tongue, soft palate, or the walls of the oropharynx (the middle part of the throat) - People who have meas...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06313450 · Sun Yat-sen University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 February 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with nasopharyngeal carcinoma (a type of cancer in the back of the nose/throat) confirmed by a pathology test, and who have not yet received any cancer treatment - People who are generally well enough to carry out light activity and care for th...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06321939 · Hunan Cancer Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - You have been recently diagnosed with nasopharyngeal cancer (a type of cancer at the back of the nose/throat), confirmed by a tissue biopsy, and have not yet received any treatment for it - Your cancer has not spread to other parts of the body (classified as stage I to IVA)...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06323239 · Sun Yat-sen University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with recurrent or metastatic nasopharyngeal carcinoma (cancer of the back of the nose/throat that has come back or spread) - People whose cancer has been confirmed by a tissue sample as a specific type of nasopharyngeal carcinoma (WHO Type II o...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06323369 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 25 March 2029
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with stage III or IVA head and neck squamous cell cancer (a specific type of head and neck cancer confirmed by lab testing), where the plan is to treat it with the aim of curing it, including surgery. - People aged 18 to 79 years old at the tim...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06336941 · University of Pisa Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2025
🇮🇹 IT

Who might be able to join this trial: - People who have been clinically diagnosed with oral squamous cell carcinoma (a type of mouth cancer) - People whose condition has been assessed as suitable for surgical treatment - People who have given their agreement to take part in the study Who may not be able to join: - Peo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06345287 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2025
🇨🇳 CN

**Who might be able to join this trial:** - People diagnosed with squamous cell carcinoma (a type of cancer) in the head and neck area who have already received 2 to 4 cycles of chemotherapy and immunotherapy, and whose medical team has recommended radiation treatment rather than surgery (either to preserve organ func...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06349889 · Sun Yat-sen University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 May 2028
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with nasopharyngeal carcinoma (a type of cancer in the back of the nose and throat), confirmed by a tissue test. - People whose cancer has been classified as stage IVA+T3N2M0 using a specific staging system called AJCC 8th edition. - People who...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06353685 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with oral cavity cancer (confirmed by tissue testing) that has not yet been treated, at a stage of T2-4N0M0 or T1-4N1-3M0 (stages II to IVB based on a standard cancer staging system) - People whose surgical tissue showed either no remaining can...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06367257 · University of Erlangen-Nürnberg Medical School Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 April 2026
🇩🇪 DE

Who might be able to join this trial: - People diagnosed with squamous cell carcinoma (a type of cancer) in the head and neck area who are receiving radiation therapy, with or without chemotherapy, either after surgery or as their main treatment - People who own a smartphone that can have the Emento app installed on it...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06380686 · AIO-Studien-gGmbH Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2029
🇩🇪 DE

**Who might be able to join this trial:** - Adults aged 18 years or older - People who are able to understand the trial information and are willing to sign a written consent form - People who have been diagnosed with squamous cell carcinoma (a type of cancer) of the head and neck — specifically in the oral cavity (mou...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06383780 · XIANG YANQUN Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 15 May 2027
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 years or older. - People who have been diagnosed with nasopharyngeal carcinoma (a type of cancer in the back of the nose and throat) confirmed by tissue or cell testing. - People whose nasopharyngeal carcinoma has spread to the bones and is not suitable for lo...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06385080 · Janssen Research & Development, LLC Phase 2 · 11 countries Recruiting
Recruiting Phase 2 Est. completion 27 December 2027
🇨🇳 CN🇫🇷 FR🇩🇪 DE🇯🇵 JP🇲🇾 MY🇵🇱 PL🇰🇷 KR🇪🇸 ES +3 more

**Who might be able to join this trial:** - You have been diagnosed with head and neck squamous cell carcinoma (a type of cancer in the throat, mouth, or voice box area) that has come back or spread, and cannot be cured with local treatments — OR (for one specific group) you have a locally advanced form of this cancer...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06389201 · Affiliated Hospital of Nantong University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2029
🇨🇳 CN

Who might be able to join this trial: - People who have been clinically diagnosed with nasopharyngeal carcinoma (NPC), a type of cancer found in the area behind the nose and throat. - People who have not yet received any treatment for their cancer. - People who are willing and able to provide informed consent (a signed...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06406530 · University of Giessen Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2025
🇩🇪 DE

Who might be able to join this trial: - People who have head and neck cancer and are planned to receive radiation therapy - People who need teeth removed on both sides of the mouth - People whose teeth being removed are of similar size to each other - People whose teeth can be removed without cutting the gum (no flap s...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06437522 · Sichuan Baili Pharmaceutical Co., Ltd. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 June 2026
🇨🇳 CN

Who might be able to join this trial: - People who have chosen to take part voluntarily and have signed a consent form - Adults aged 18 to 75 years (male or female) - People whose doctors expect them to live for at least 3 more months - People who are fully active or have only minor restrictions on physical activity (c...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06444776 · Sonja Stieb, MD Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2025
🇨🇭 CH

**Who might be able to join this trial:** - People who have been diagnosed with head and neck cancer - People who have been referred for radiation therapy aimed at curing their cancer, whether as the main treatment or after surgery - People who are 18 years of age or older - People whose general health and ability to c...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06448026 · M.D. Anderson Cancer Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 15 May 2027
🇺🇸 US

**Who might be able to join this trial:** - Adults aged 18 or older who have been diagnosed with squamous cell carcinoma (a type of cancer) of the mouth, or a specific type of throat cancer that has tested negative for HPV (a virus) - People whose cancer has come back in the same area where it first started (not sprea...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06455410 · Sun Yat-sen University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 18 June 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who have been fully informed about the study and have signed a written consent form - Adults aged 18 to 65 years, either men or women who are not pregnant - People who have been diagnosed through a tissue biopsy with a specific type of nasopharyngeal cancer (non-kerat...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06457503 · Coherus Oncology, Inc. Phase 4 · 2 countries Recruiting
Recruiting Phase 4 Est. completion 1 December 2027
🇨🇦 CA🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with nasopharyngeal cancer (a type of cancer in the back of the nose and throat) that has come back or spread, confirmed through a tissue or cell sample, regardless of whether it is linked to the Epstein-Barr virus (EBV) or not. - People whose...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT06465628 · The University of Hong Kong Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
Hong Kong

**Who might be able to join this trial:** - People aged 18 or older - People who are able to give informed consent to take part in research - People who have been diagnosed with a head and neck cancer, such as oral cancer, nasopharyngeal cancer, oropharyngeal cancer, hypopharyngeal cancer, laryngeal cancer, sinus cance...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06468852 · Beijing Tongren Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 April 2026
🇨🇳 CN

**Who might be able to join this trial:** - Adults aged 18 or older - People scheduled for head and neck cancer surgery (such as for nasopharyngeal carcinoma, larynx cancer, hypopharyngeal cancer, or other head and neck cancers — but not thyroid cancer), where the surgery is expected to last 2 hours or more - People wh...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06469008 · Sichuan Baili Pharmaceutical Co., Ltd. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 July 2026
🇨🇳 CN

Who might be able to join this trial: - People who are willing to sign a consent form and follow the study requirements - People of any gender aged 18 to 75 years (for Phase Ia of the study) or aged 18 and older (for Phase Ib of the study) - People with a life expectancy of at least 3 months - People who have been diag...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06470217 · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong Univ... Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 19 June 2025
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 75 years, of any sex - People diagnosed with a specific type of mouth cancer (squamous cell carcinoma of the oral cavity) that is at stage III or IVa and can be removed with surgery, confirmed by a tissue test, with tumours large enough to measure on a CT s...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06472570 · Maria Sklodowska-Curie National Research Institute of Oncology Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2030
🇵🇱 PL

**Who might be able to join this trial:** - People aged 18 to 80 years with squamous cell carcinoma or adenoid cystic carcinoma in the head and neck area who are scheduled for radical radiotherapy or combined radiation and chemotherapy (either as a primary treatment or after surgery). - People aged 18 to 80 years with...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06472713 · Ming-Yuan Chen Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 October 2025
🇨🇳 CN

**Who might be able to join this trial:** - People who are willing to take part, sign a consent form, and follow all study visits, treatments, and tests as required. - People who have been diagnosed with nasopharyngeal carcinoma (a type of cancer at the back of the nose) confirmed by a tissue biopsy, specifically the...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06477692 · University of Texas Southwestern Medical Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 July 2028
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with a confirmed squamous cell carcinoma (a type of cancer) located in the oropharynx (back of the throat/tonsils/base of tongue), larynx (voice box), or hypopharynx (lower throat) — the cancer must have a known starting location. - Your cancer can be...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06479070 · Institut de Cancérologie de Lorraine Not Applicable · 2 countries Recruiting
Recruiting Not Applicable Est. completion 30 September 2026
🇫🇷 FR🇨🇭 CH

**Who might be able to join this trial:** - People who have a general health status rated as reasonably functional (scored 0 to 2 on a standard medical scale) - People who have been newly diagnosed with a specific type of head and neck cancer (squamous cell carcinoma of the upper airways or digestive tract), confirmed...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06487403 · University Health Network, Toronto Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2028
🇨🇦 CA

**Who might be able to join this trial:** - You are 18 years old or older - You have been diagnosed with a specific type of head and neck cancer (squamous cell carcinoma), confirmed by a tissue sample test - Your cancer tumour or affected lymph node is larger than 3cm - You are generally well enough to carry out some...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06492460 · Sun Yat-sen University Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 20 September 2029
🇨🇳 CN

**Who might be able to join this trial:** - People diagnosed with head and neck squamous cell carcinoma (a specific type of cancer affecting the head and neck area) at Stage III or Stage IV - People who have already had surgery to remove the cancer, where the surgery showed either cancer had spread outside nearby lymp...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06531083 · University of Alberta Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2026
🇨🇦 CA

Who might be able to join this trial: - People who have been diagnosed with oral, oropharyngeal, or nasopharyngeal cancer - People who are scheduled to receive cancer treatment that includes radiation therapy - People who are able to read and understand English - People who currently live in Alberta, Canada Who may no...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06532279 · NRG Oncology Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 January 2027
🇺🇸 US

**Who might be able to join this trial:** - The treatment plan must include radiation therapy combined with cisplatin chemotherapy as the main (definitive) treatment — not as treatment given after surgery. - At least two specific areas of the mouth or throat (such as the tongue, tonsils, soft palate, hard palate, chee...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06533267 · Sun Yat-sen University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 25 March 2034
🇨🇳 CN

Who might be able to join this trial: - People who have a general health and functioning score above 70 on a standard medical scale (called the Karnofsky score), meaning they are largely able to carry out normal daily activities - People who have been confirmed by laboratory testing to have a specific type of nasophary...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06540443 · MegaPro Biomedical Co. Ltd. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 June 2026
🇹🇼 TW

**Who might be able to join this trial:** - People aged 20 years or older - People who have been diagnosed through a tissue biopsy with a specific type of head and neck cancer (squamous cell carcinoma), or who have suspicious lymph nodes that may indicate cancer spread, at a certain stage of disease, and who have not...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06549946 · Psivac Ltd Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 January 2027
🇬🇧 GB

Who might be able to join this trial: - People who are able to give their full informed consent and understand what taking part in the trial involves - Adults aged 18 or older (or older if local laws require a higher age of consent) - People who have solid tumour cancers that have spread, cannot be surgically removed,...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06550050 · M.D. Anderson Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2064
🇺🇸 US

Who might be able to join this trial: - Adults aged 18 or older who have been diagnosed with, or are being assessed for, a precancerous or cancerous condition in the mouth, including leukoplakia, erythroplakia, mild/moderate/severe dysplasia, carcinoma in situ, or squamous cell carcinoma. - People who are attending UT...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06554158 · Georgetown University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 or older at the time of signing the consent form. - People diagnosed with a specific type of throat cancer (squamous cell carcinoma of the oropharynx) that tests positive for p16 and/or HPV, affecting areas such as the base of the tongue, tonsils, soft palate,...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06570486 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2024
🇨🇳 CN

Who might be able to join this trial: - People who have had a head or neck tumour (cancer in the head or neck area) - People who are older than 18 years of age Who may not be able to join: - People who have been transferred to the intensive care unit (ICU) two or more times after treatment for a head or neck tumour -...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06575322 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2026
🇨🇳 CN

Who might be able to join this trial: - People who have been clinically diagnosed with head and neck squamous cell carcinoma (a type of cancer affecting the head and neck area) at stage I through IVA, with no prior treatment received, and who are planning to have either surgery alone or surgery combined with chemothera...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06579248 · Henry Ford Health System Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 30 August 2026
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with a specific type of throat/voice box cancer (squamous cell carcinoma of the larynx) that is at an advanced local stage and are being treated with both radiation therapy and chemotherapy together as your main treatment. - You are 18 years of age or...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT06580054 · University of Michigan Rogel Cancer Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 March 2028
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 or older who have given written consent to participate. - People with a laboratory-confirmed diagnosis of locally advanced, diffuse, or returning skin cancer (squamous cell carcinoma) in or around the eye socket area. - Women who are not pregnant, not breastfe...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06589609 · BlueSky Immunotherapies GmbH Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 November 2027
🇦🇹 AT

**Who might be able to join this trial:** - Adults aged 18 to 65 who have been newly diagnosed with a specific type of throat cancer (oropharyngeal squamous cell carcinoma) that has tested positive for both p16 and HPV16, and has reached an advanced but locally contained stage (confirm specific staging details with tr...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06592599 · Stanford University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 January 2029
🇺🇸 US

**Who might be able to join this trial:** - People diagnosed with locoregionally advanced, EBV-positive nasopharyngeal cancer (a specific type of head and neck cancer) at certain stages, with no spread to distant parts of the body (confirm with trial site for exact staging details) - People who have not previously rec...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06593639 · Laura Deborah Locati Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2026
🇮🇹 IT

**Who might be able to join this trial:** - People aged 18 or older - People whose cancer is being treated with the aim of a cure, using chemotherapy with radiation therapy, or surgery with radiation therapy (with or without chemotherapy) - People who are in good general health and able to carry out daily activities wi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06601309 · Fujian Medical University Union Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 July 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with esophageal squamous cell carcinoma (a specific type of oesophageal cancer), confirmed through a tissue sample test - People whose cancer is at a locally advanced but potentially operable stage (stage II or III, meaning it has not spread to...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06601335 · Akeso Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 January 2027
🇨🇳 CN

**Who might be able to join this trial:** - People who are able and willing to sign a written consent form agreeing to take part. - People whose general health and ability to carry out daily activities is rated as fully active or restricted only in physically strenuous activity (this is measured on a standard scale ca...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06606028 · University of California, San Francisco Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 December 2028
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with squamous cell carcinoma (a type of cancer) affecting the head and neck area, including the mouth, throat, or skin, confirmed through a tissue or cell sample. - People who are 18 years of age or older. - People who are planning to receive surger...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06607406 · Wake Forest University Health Sciences Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2030
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with a specific type of cancer called squamous cell carcinoma, confirmed by a laboratory test, located in the mouth, throat, voice box, lower throat, sinuses, or neck lymph nodes with an unknown starting point. - People whose treatment plan inc...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06611137 · Sun Yat-sen University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 11 September 2025
🇨🇳 CN

Who might be able to join this trial: - People diagnosed with laryngeal (voice box) cancer at a specific stage (T3-4, N0-3, M0) or hypopharyngeal (lower throat) cancer at a specific stage (T2-4, N0-3, M0), as classified by the AJCC 8th edition staging system (confirm with trial site) - People aged between 18 and 70 yea...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06623266 · Huashan Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 September 2026
🇨🇳 CN

**Who might be able to join this trial:** - The cancer is located in one of these areas of the mouth: the tongue, gums, inner cheek lining, floor of the mouth, roof of the mouth (hard palate), or the retromolar area (behind the back teeth) - The cancer has been assessed as an early stage, specifically classified as cT1...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06627075 · Center Eugene Marquis Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 12 October 2026
🇫🇷 FR

Who might be able to join this trial: - People who are 18 years of age or older - People who are receiving palliative or curative treatment for cancer of the mouth, nose, or throat area - People whose treatment plan includes radiotherapy, with or without additional treatments such as chemotherapy or immunotherapy, for...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06627270 · Case Comprehensive Cancer Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 October 2026
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with a type of mouth cancer called squamous cell carcinoma, confirmed through laboratory testing of tissue - People who are scheduled to have surgery with the goal of curing their cancer - People who are 18 years of age or older - People who are abl...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06629038 · National Taiwan University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇹🇼 TW

Who might be able to join this trial: - Adults who are in good general health with no history of injury or surgery involving the head, neck, or shoulders, and who have not had radiation or chemotherapy treatment for head and neck cancer - People who have been diagnosed with oral cancer and who have developed limited ja...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06629597 · MediLink Therapeutics (Suzhou) Co., Ltd. Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 December 2027
🇨🇳 CN

**Who might be able to join this trial:** - People who are willing and able to sign a written consent form to take part in the study. - People aged 18 to 75 years old, of any gender. - People whose general physical functioning is rated at 0 or 1 on a standard activity scale used by doctors (meaning they are fully acti...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06630780 · Sun Yat-sen University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2029
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with head and neck squamous cell carcinoma (a type of cancer in the head and neck area) confirmed by a laboratory test before surgery, and who are receiving it as their first treatment - People who have received a combination of chemotherapy an...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06633224 · University of California, San Francisco Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2026
🇺🇸 US

Who might be able to join this trial: - People who have not received any cancer treatment (such as systemic therapies or radiation therapy) in the past month, except for surgery or introductory chemotherapy. - People who are scheduled to receive 15 or more treatment sessions (fractions) of radiation. - People who are m...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06634030 · Vanderbilt University Medical Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 June 2026
🇺🇸 US

**Who might be able to join this trial:** - People who have had surgery (either Mohs micrographic surgery or wide local excision) to completely remove a skin cancer on the head or neck, leaving a full-thickness wound between 1.5 and 10 centimetres at its widest point, with clear edges confirmed by a pathology report....

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06636188 · The University of Hong Kong Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2027
Hong Kong

Who might be able to join this trial: - People aged 18 or older - People who can read and speak Cantonese or Mandarin fluently - People who have recently received a first-time, primary diagnosis of head and neck or laryngeal (voice box) cancer - People who are waiting to receive a full course of radiation therapy aimed...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06636734 · Emory University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2027
🇺🇸 US

**Who might be able to join this trial:** - Adults aged 18 or older who are able to give informed consent to participate - People who have been diagnosed through laboratory testing with head and neck squamous cell cancer (a type of cancer affecting the mouth, throat, voice box, nasal passages, or sinuses) that has com...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06640725 · Groupe Oncologie Radiotherapie Tete et Cou Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 2 October 2027
🇫🇷 FR

**Who might be able to join this trial:** - Adults aged 18 to 74 years old - People with a confirmed diagnosis of squamous cell cancer of the head and neck (mouth, throat, or voice box) that has come back or spread, and cannot be treated with surgery or radiation aimed at curing it; or people with squamous cell cancer...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06641791 · Canadian Cancer Trials Group Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 January 2031
🇨🇦 CA

**Who might be able to join this trial:** - People who have been diagnosed (confirmed by tissue testing) with a type of cancer called squamous cell carcinoma affecting the moist lining of the head and neck area — specifically from the throat (oro/hypopharynx), mouth, upper voice box, the sinus near the cheek, nasal ca...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06642324 · Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 March 2025
Bangladesh

Who might be able to join this trial: - Adults aged 18 years or older. - People who have been diagnosed with head and neck squamous cell carcinoma (a specific type of cancer) confirmed by a tissue biopsy. - People whose cancer is located in one of these specific areas: the mouth, throat (oropharynx), lower throat (hypo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06648096 · Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau Phase 2 · 2 countries Recruiting
Recruiting Phase 2 Est. completion 1 December 2028
🇩🇪 DE🇪🇸 ES

Who might be able to join this trial: - People aged 18 or older who have signed and dated a consent form before any trial procedures begin. - People who have been diagnosed with Fanconi anemia. - People who have been confirmed (through tissue or cell testing) to have a type of head or neck cancer called squamous cell c...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06657222 · Tubulis GmbH Phase 2 · 4 countries Recruiting
Recruiting Phase 2 Est. completion 1 December 2028
🇨🇦 CA🇷🇴 RO🇪🇸 ES🇺🇸 US

Who might be able to join this trial: - Adults aged 18 or older who are male, or female and neither pregnant nor breastfeeding - People whose major organs (such as liver, kidneys, and bone marrow) are functioning adequately - People who had previous cancer treatments (such as chemotherapy, biological therapy, hormone t...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06657690 · Sun Yat-sen University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 October 2026
🇨🇳 CN

Who might be able to join this trial: - People who are willing to take part, sign a consent form, and follow all study visits, treatments, and tests as required. - People aged 18 years or older. - People who have been diagnosed with nasopharyngeal carcinoma (a type of head and neck cancer) confirmed by a tissue biopsy,...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06659146 · King's College London Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2028
🇬🇧 GB

Who might be able to join this trial: - People who have been diagnosed with a cancer that cannot be cured or removed by surgery, and who have at least one tumour near the surface of the skin or in a lymph node that is suitable for treatment with a specific heat-based device (the hydrosun® TWH1500) - People who are alre...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06662929 · King Saud University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2025
🇸🇦 SA

Who might be able to join this trial: - Adults aged 18 or older who are planned to receive, are currently receiving, or have already received radiation therapy for head and neck cancer at King Saud University Medical City. Who may not be able to join: - People who are under 18 years of age. - People who have a serious...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06667427 · M.D. Anderson Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2026
🇺🇸 US

Who might be able to join this trial: **For the active treatment group:** - Willing and able to sign a consent form agreeing to take part in the study - Aged 18 or older - Already scheduled to have a facial nerve transfer procedure - Willing to follow all study requirements and available to participate for the full du...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06668961 · Sichuan Baili Pharmaceutical Co., Ltd. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 November 2026
🇨🇳 CN

Who might be able to join this trial: - Adults aged 18 to 75 years old - People with head and neck squamous cell carcinoma (a type of cancer) that has come back or spread to other parts of the body - People with a life expectancy of at least 3 months - People who are generally well enough to carry out light activity (w...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06673693 · Sun Yat-sen University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2027
🇨🇳 CN

Who might be able to join this trial: - People who have been diagnosed with head and neck squamous cell carcinoma (a type of head and neck cancer confirmed by laboratory testing) that has already received some initial treatment and can be surgically removed. - People whose cancer is classified as stage III to IVB (usin...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06676592 · Memorial Sloan Kettering Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2027
🇺🇸 US

**Who might be able to join this trial:** - You are 18 years of age or older - You are scheduled to have a head and neck surgery at the Surgery Head and Neck Service at MSK - You are scheduled to have standard pre-surgery imaging (such as an ultrasound, CT scan, MRI, or PET scan) in the Radiology Service at MSK — or, i...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06678724 · National Taiwan University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2027
🇹🇼 TW

Who might be able to join this trial: - People aged 20 years or older. - People who have a performance status score of 0 to 2 on the ECOG scale, which is a measure of how much a person's cancer affects their daily activities (confirm with trial site). - People who have been diagnosed through laboratory testing with squ...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06681935 · Medical College of Wisconsin Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 July 2026
🇺🇸 US

Who might be able to join this trial: - People who are able to give their own signed and dated consent to participate. - People who are willing to follow all study procedures and remain available for the full duration of the study. - People who are 21 years of age or older. - People who are already scheduled to have or...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06682442 · University of California, San Francisco Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 May 2029
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with nasopharyngeal carcinoma (a type of cancer in the back of the nose/throat), confirmed by a tissue or cell sample from the tumor or nearby lymph nodes. - Your cancer is linked to the Epstein-Barr virus (EBV), shown by a detectable level of EBV in...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06682494 · Virginia Commonwealth University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 October 2027
🇺🇸 US

Who might be able to join this trial: - People who identify as African American, as defined by the US Census - People who are able to read, speak, and write in English Who may not be able to join: - People who are unable to participate in the research project due to a physical or mental health reason - Adults who are...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06682793 · A2 Biotherapeutics Inc. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 March 2029
🇺🇸 US

**Who might be able to join this trial:** - People who are already enrolled in a related study called BASECAMP-1 (run by A2 Biotherapeutics, Inc.) and whose tumour tissue testing has shown a specific genetic feature called loss of HLA-A\*02, detected by a type of genetic sequencing test. - People who have been confirm...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06686342 · Huashan Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 11 November 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with recurrent or metastatic head and neck squamous cell carcinoma (a specific type of head and neck cancer), confirmed by laboratory testing - People who have tumor tissue available that can be used to grow cancer cell cultures for the study -...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06686979 · Huashan Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 November 2026
🇨🇳 CN

Who might be able to join this trial: - People who have been diagnosed with recurrent or metastatic salivary gland cancer, confirmed by a laboratory test on a tissue sample. - People who have tumour tissue available that can be used to grow cancer cell cultures for the study. - People whose general health and ability t...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06688760 · Ming-Yuan Chen Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2028
🇨🇳 CN

**Who might be able to join this trial:** - People who are generally well and active, with a performance status score of 0 or 1 (meaning able to carry out normal daily activities with little or no restriction) - People diagnosed with a specific type of nasopharyngeal cancer (a cancer at the back of the nose/throat), co...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06693323 · University of California, Irvine Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2027
🇺🇸 US

**Who might be able to join this trial:** - People aged between 18 and 79 years old. - People who have been diagnosed with head and neck squamous cell cancer (a type of cancer affecting the mouth, throat, or related areas) that has tested positive for the HPV virus, confirmed through a tissue or cell sample. - People...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06699212 · Rakuten Medical, Inc. Phase 3 · 3 countries Recruiting
Recruiting Phase 3 Est. completion 1 September 2028
🇯🇵 JP🇹🇼 TW🇺🇸 US

Who might be able to join this trial: - People who have been confirmed by tissue or cell testing to have squamous cell carcinoma (a type of cancer) starting in the head or neck area (not including the nasopharynx or a skin-based type called cuSCC). - People whose cancer has come back and for whom doctors consider stand...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06706401 · Centre Leon Berard Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 January 2029
🇫🇷 FR

**Who might be able to join this trial:** - Adults aged 18 or older at the time of signing the consent form. - People diagnosed for the first time with a specific type of head and neck cancer (squamous cell carcinoma) confirmed by a tissue sample, located in the oropharynx, larynx, or hypopharynx, at certain defined s...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06708754 · NYU Langone Health Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 13 February 2028
🇺🇸 US

**Who might be able to join this trial:** - You have had radiation treatment for head and neck cancer, and it has been at least 3 months but less than 36 months (3 years) since your last radiation treatment. - You received at least 50Gy (a measure of radiation dose) of radiation to both sides of your neck, either with...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06712888 · Sun Yat-sen University Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 January 2030
🇨🇳 CN

**Who might be able to join this trial:** - People who are willing to take part and sign a consent form agreeing to participate. - People aged between 18 and 70 years, who are male or female and not pregnant. - People who have been confirmed by a tissue test to have a specific type of nasopharyngeal cancer (a cancer a...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06725498 · Beijing Tongren Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 November 2026
🇨🇳 CN

**Who might be able to join this trial:** - People diagnosed with a specific advanced stage of head and neck squamous cell carcinoma (a type of cancer affecting the throat, voice box, mouth, or related areas), confirmed by laboratory testing of tissue or cell samples. - People whose cancer has not spread to distant pa...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06736379 · VLP Therapeutics Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 30 December 2027
🇺🇸 US

Who might be able to join this trial: - People aged 18 or older with head and neck cancer that cannot be surgically removed, or that has come back or spread, with at least one tumour that can be injected directly and is not planned for surgical removal — and who have previously received certain treatments including pla...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06737822 · All India Institute of Medical Sciences, Jodhpur Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 October 2027
🇮🇳 IN

**Who might be able to join this trial:** - People who have been newly diagnosed with oral squamous cell cancer (a type of mouth cancer) and have not yet received any treatment, confirmed by a tissue or cell sample test - People whose cancer has been staged as a certain level of local and regional spread (clinical Sta...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06741982 · West China Hospital Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 15 December 2026
🇨🇳 CN

Who might be able to join this trial: - People aged 18 to 70 years old, of any gender - People who have been confirmed by tissue testing to have a type of head and neck cancer called squamous cell carcinoma (not including nasopharyngeal, salivary gland, or thyroid cancers), that has not spread to distant parts of the b...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06744296 · Massachusetts Eye and Ear Infirmary Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 6 January 2027
🇺🇸 US

**Who might be able to join this trial:** - People who have been newly diagnosed with Stage III to Stage IVB squamous cell cancer (a type of cancer) in the mouth, nose, sinuses, throat, voice box, or related areas of the head and neck, based on the AJCC 8th edition staging system. - People who have tumor tissue availa...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06752798 · Hunan Cancer Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 September 2025
🇨🇳 CN

Who might be able to join this trial: - People who have been diagnosed through a biopsy or tissue sample with locally advanced squamous cell carcinoma (a specific type of cancer) in the head and neck area — including the mouth, throat, voice box, or lower throat — but not the lip or nasopharynx (the upper part of the t...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06755762 · Chang Gung Memorial Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 July 2025
🇹🇼 TW

**Who might be able to join this trial:** - You are 18 years of age or older - You agree to have blood drawn and follow the steps required by the trial - (For healthy volunteers) You have not had cancer in the last 5 years - (For cancer patients) You have been diagnosed with head and neck cancer that has spread to othe...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06761937 · Erasmus Medical Center Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 February 2027
🇳🇱 NL

**Who might be able to join this trial:** - Adults aged 18 or older. - People with a good general health and activity level, rated 0 or 1 on the WHO performance scale (meaning fully active or able to carry out light work). - People with a mouth opening of at least 40mm (for women) or 45mm (for men) before treatment be...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06767488 · Nanfang Hospital, Southern Medical University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2025
🇨🇳 CN

Who might be able to join this trial: - People who are willing to voluntarily sign a consent form to take part in the study. - People who are 18 years of age or older. - People who have been diagnosed with a head and neck tumour, confirmed through a tissue sample (biopsy), and who have been treated with radiation thera...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06781567 · HitGen Inc. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2028
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 or older, of any gender, who have signed a consent form and are able to follow the study requirements. - People diagnosed with adenoid cystic carcinoma (a type of cancer) that has come back or spread to other parts of the body, and where the disease has shown...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06785051 · National Taiwan University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 July 2027
🇹🇼 TW

Who might be able to join this trial: - You have recently been diagnosed with oral cancer and are planning to receive treatment such as surgery, radiation therapy, chemotherapy, or a combination of these. - You are between 20 and 65 years old. Who may not be able to join: - You are unable to communicate (for example,...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06791941 · Regina Elena Cancer Institute Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 7 March 2029
🇮🇹 IT

Who might be able to join this trial: - People aged 18 or older - People who have been diagnosed with a squamous cell (a specific type of cancer cell) tumour in the mouth, throat, or voice box - People who are having surgery as the main treatment for their head and neck cancer, with no previous cancers in other parts o...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06794372 · John O. Prior Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 October 2026
🇨🇭 CH

**Who might be able to join this trial:** - People who are 18 years of age or older - People whose general health and ability to carry out daily activities meets a certain minimum level, as measured by a standard performance scale (Karnofsky index ≥80%) (confirm with trial site) - People who have been diagnosed with a...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06796270 · The Second Affiliated Hospital of Hainan Medical University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - People aged between 18 and 75 years old, of any gender - People whose general physical functioning meets a certain level of fitness for treatment (confirm with trial site) - People who have been diagnosed with a specific type of nasopharyngeal cancer (cancer of the back of t...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06802835 · Sun Yat-sen University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 June 2027
🇨🇳 CN

**Who might be able to join this trial:** - People diagnosed with nasopharyngeal carcinoma (a type of cancer in the back of the nose and throat) whose cancer has come back or spread after initial or intensive treatment - People aged between 18 and 75 years old, of any gender - People who have a confirmed diagnosis of...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06803147 · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 7 February 2038
🇳🇱 NL

**Who might be able to join this trial:** - People who have been diagnosed with non-dysplastic Barrett's esophagus (a condition where the lining of the food pipe changes, but without any abnormal cell changes) - People whose Barrett's esophagus area is shorter than 5 cm in length - People who have had at least one rec...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06805617 · Glenn J. Hanna Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 July 2026
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with salivary gland cancer (any type) through a tissue sample, where the cancer has come back, spread to other parts of the body, or cannot be surgically removed. - People who are willing to provide stored tumor tissue from a previous biopsy or...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06811844 · The First Affiliated Hospital of Xiamen University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2027
🇨🇳 CN

**Who might be able to join this trial:** - People aged between 18 and 65 years old - People who have been diagnosed with nasopharyngeal carcinoma (a type of cancer in the back of the nose/throat) confirmed by a tissue or cell sample, at a specific stage of the disease (stage T1-4, N2-3, M0 — meaning it has spread to...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06819228 · Vanderbilt-Ingram Cancer Center Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 March 2028
🇺🇸 US

**Who might be able to join this trial:** - People who are willing to read and sign a consent form agreeing to take part in the study. - Adults aged 18 or older (male or female). - People who have had their cancer confirmed through a tissue sample as squamous cell carcinoma of the head and neck. - People for whom surg...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06823479 · The Netherlands Cancer Institute Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 February 2029
🇳🇱 NL

Who might be able to join this trial: - People aged 18 years or older - People with skin squamous cell carcinoma (a type of skin cancer) caused by UV exposure, at an early to advanced stage (Stage I to IVa), where treatment would require extensive or disfiguring surgery - People with either advanced-stage skin squamous...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06829147 · Sun Yat-sen University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2026
🇨🇳 CN

Who might be able to join this trial: - You have been diagnosed with nasopharyngeal carcinoma (a type of cancer in the back of the nose/throat), confirmed by a tissue sample (biopsy), classified as Type I, II, or III by the World Health Organization. - You had an MRI scan done at the time of first diagnosis, before any...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06831149 · Matthew Spector Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 28 February 2028
🇺🇸 US

Who might be able to join this trial: - People who have previously been diagnosed with a confirmed (biopsy-proven) squamous cell carcinoma (a type of cancer) of the voice box (larynx) or the area around it (hypopharynx), at stage II through to stage IV - People who have previously been treated with radiation therapy, w...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06837480 · Abramson Cancer Center at Penn Medicine Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 August 2029
🇺🇸 US

**Who might be able to join this trial:** - People who are over 18 years old - People who have had head and neck cancer confirmed by a biopsy - People who have no signs of cancer at the time of joining the study, between 12 and 60 months after finishing cancer treatment - People who have had lymphedema (swelling cause...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06851247 · Sun Yat-sen University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 June 2027
🇨🇳 CN

Who might be able to join this trial: - People who are willing to take part and sign a consent form in person. - People aged 18 to 65 years old, who are male or female and not pregnant. - People who have been diagnosed with a specific type of nasopharyngeal cancer (a cancer at the back of the nose/throat), confirmed by...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06856213 · Grupo Español de Tratamiento de Tumores de Cabeza y Cuello Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 October 2028
🇪🇸 ES

**Who might be able to join this trial:** - People aged 18 or older who have given written, voluntary agreement to take part in the study and are willing and able to attend scheduled visits and follow the study plan. - People who have been diagnosed with squamous cell carcinoma of the head and neck, confirmed by a tis...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06869473 · Gruppo Oncologico del Nord-Ovest Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 20 August 2027
🇮🇹 IT

**Who might be able to join this trial:** - People aged 18 or older who are able to sign a consent form - People with a confirmed diagnosis of head and neck squamous cell cancer (a specific type of cancer affecting areas such as the mouth, throat, voice box, or lower throat), based on laboratory analysis of tissue or...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06870799 · University of Zurich Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2027
🇨🇭 CH

**Who might be able to join this trial:** - People who are able to give written consent to participate, in line with Swiss law and international clinical trial standards, before any trial procedures begin - People who have a medical reason to receive radiotherapy to the head and neck area, regardless of the type of tum...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06886347 · Chen Xiaozhong Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 April 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who have voluntarily signed a consent form agreeing to take part in the study. - People aged 18 to 75 years old at the time of joining. - People whose general physical health and ability to carry out daily activities is rated as fully active or restricted only in phys...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06896695 · Roswell Park Cancer Institute Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 25 February 2027
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with head and neck cancer - People who screen positive for financial hardship on a validated financial difficulty questionnaire called the Comprehensive Score for Financial Toxicity (COST) measure - People who are able to participate in English or S...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06905145 · National Cancer Institute, Naples Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2026
🇮🇹 IT

Who might be able to join this trial: - People who are older than 18 years of age - People who are able to provide written consent to participate, as approved by an ethics committee - People who have been diagnosed through a tissue test with squamous cell carcinoma (a type of cancer) located in the head and neck area,...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06905561 · The Second Affiliated Hospital of Hainan Medical University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2026
🇨🇳 CN

**Who might be able to join this trial:** - You are 18 years of age or older (male or female) - You are physically able to carry out daily activities with little or no difficulty (confirm with trial site) - You have been diagnosed with a specific type of cancer affecting the throat, nose, voice box, sinuses, salivary...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06913296 · Aristotle University Of Thessaloniki Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 May 2025
🇬🇷 GR

Who might be able to join this trial: - People who are older than 18 years of age - People whose overactive parathyroid gland is caused by a benign growth called an adenoma (a type of non-cancerous tumour on the parathyroid gland) - People who have given their written agreement to take part in the trial Who may not be...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06915038 · Indiana University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2028
🇺🇸 US

**Who might be able to join this trial:** - You are 18 years of age or older at the time of signing consent - You are able to sign a consent form and authorize use of your health information - You are generally able to carry out daily activities, with little to no limitation from your condition (confirm with trial sit...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06915454 · Vanderbilt-Ingram Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2027
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with any type of solid tumour, confirmed by biopsy - People whose cancer is at any stage or location, and who are scheduled to have surgery to remove the tumour all at once — including people with cancer that has come back or a new cancer that...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06915727 · Mayo Clinic Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 May 2027
🇺🇸 US

Who might be able to join this trial: - The patient (or their parent or legal guardian) is willing and able to give written consent to participate - The patient is between 6 months and 17 years of age - The patient has been diagnosed with, or is strongly suspected to have, a solid tumour located in the neck, chest, abd...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06935188 · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong Univ... Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2028
🇨🇳 CN

**Who might be able to join this trial:** - You are between 18 and 75 years old (any sex). - You have been diagnosed with squamous cell carcinoma of the head and neck that has been confirmed by a tissue biopsy, and the cancer has either come back after surgery, spread to other parts of the body, or cannot be removed w...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06940180 · Glenn J. Hanna Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 February 2028
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with cancer of the nasal cavity or sinuses, confirmed by laboratory testing of tissue or cells, and the cancer type must be squamous cell carcinoma (including certain variations) or sinonasal undifferentiated carcinoma (SNUC). - People whose ca...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06941727 · National Taiwan University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇹🇼 TW

Who might be able to join this trial: - People who have been newly diagnosed with oral cancer and are scheduled to receive cancer-related treatment, such as surgery, radiotherapy, chemotherapy, or a combination of chemotherapy and radiotherapy. - People between the ages of 20 and 65 years. Who may not be able to join:...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06952868 · China Medical University Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 August 2026
🇹🇼 TW

**Who might be able to join this trial:** - People aged 18 to 80 years old. - People who have been diagnosed with head and neck cancer (confirmed by lab testing of tissue or cells) that has not spread to distant parts of the body. - People with a type of head and neck cancer called squamous cell carcinoma (SCC) that h...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06959082 · VSPharmTech Co.,Ltd. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 June 2027
🇺🇸 US

Who might be able to join this trial: - Adults aged 18 or older at the time of signing the consent form - People who have been diagnosed with squamous cell carcinoma (a type of cancer) in the mouth, throat, voice box, or related areas in the head and neck, confirmed by a tissue or cell sample, and detected using PET, C...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06968520 · Nanfang Hospital, Southern Medical University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 November 2025
🇨🇳 CN

**Who might be able to join this trial:** - People who have signed an informed consent form agreeing to take part in the study - People whose cancer has been confirmed through a tissue biopsy as nasopharyngeal carcinoma (a type of cancer at the back of the nose) or another head and neck cancer - People for whom radioth...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06978829 · Daping Hospital and the Research Institute of Surgery of the Third Mil... Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 March 2027
🇨🇳 CN

Who might be able to join this trial: - People who are willing to take part, have signed a consent form, and are able to follow the study procedures - People who have been confirmed by laboratory testing (cell or tissue samples) to have locally advanced head and neck squamous cell carcinoma (a type of cancer in the hea...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06982300 · University Medical Center Groningen Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2026
🇳🇱 NL

**Who might be able to join this trial:** - You have been diagnosed with nasopharyngeal cancer (a type of cancer in the back of the nose/throat) at a certain stage (Stage IB to IVA), and your cancer has tested positive for a virus called Epstein-Barr virus (EBV) - Your doctors are planning to treat you with chemothera...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06984861 · Memorial Sloan Kettering Cancer Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 May 2028
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with HPV-associated squamous cell carcinoma (a type of cancer linked to the HPV virus) of the oropharynx — which includes the tonsils, base of the tongue, or the walls of the throat — confirmed by a tissue or cell sample from a biopsy or surger...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06985784 · City of Hope Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 9 November 2027
🇺🇸 US

Who might be able to join this trial: **For patients:** - People aged 18 or older - People who have normal vision and hearing, or vision and hearing that is fully corrected (for example, with glasses or hearing aids) - People who are able to walk, including with the help of a cane or crutch - People who can read and u...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06992427 · Alliance for Clinical Trials in Oncology Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 15 August 2029
🇺🇸 US

**Who might be able to join this trial:** - People diagnosed with squamous cell carcinoma (a specific type of cancer) in the head and neck area, at any stage from I to IV - People who have not had any previous treatment for head and neck cancer - People whose doctors have planned treatment using a chemotherapy drug ca...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06995508 · Roswell Park Cancer Institute Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 15 November 2030
🇺🇸 US

**Who might be able to join this trial:** - Adults aged 18 or older - People whose general health and ability to function day-to-day is rated at a certain level (a score of 2 or less on a standard oncology scale, where lower scores mean fewer limitations — confirm with trial site) - People who have been diagnosed with...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06997068 · Mayo Clinic Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 June 2028
🇺🇸 US

**Who might be able to join this trial:** - You are 18 years of age or older - You have been diagnosed with head and neck cancer (mouth, throat, voice box, or related areas — including HPV-positive and HPV-negative types) that has come back or spread, confirmed by a tissue biopsy - Your cancer can be measured on a sca...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06997094 · Mayo Clinic Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 8 November 2027
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 or older - People who have been diagnosed with a specific type of head and neck cancer (HPV-negative squamous cell carcinoma) that can be removed by surgery, including cases where the original site of the cancer is unknown - People whose cancer can be measured...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06998069 · Brown University Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 June 2026
🇺🇸 US

**Who might be able to join this trial:** - A biopsy or tissue test has confirmed a diagnosis of squamous cell carcinoma (a type of cancer) in the head or neck area — not including cases where the original source of the cancer is unknown. - Scans and imaging have confirmed the cancer is at a stage between IB and IVA (...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07000643 · Man Hu Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 28 February 2027
🇨🇳 CN

**Who might be able to join this trial:** - People who have given written consent before any trial procedures begin - Adults aged 18 to 75 years (any gender) - People with a tissue-confirmed diagnosis of nasopharyngeal carcinoma (a type of cancer in the back of the nose/throat), classified under the latest WHO guideli...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07007364 · Jun Jia Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 June 2026
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 70 years old, any gender - People whose cancer has been confirmed by a tissue sample (biopsy) to be squamous cell carcinoma in the mouth — specifically in the front two-thirds of the tongue, floor of the mouth, gums, inner cheeks, hard palate, or the area b...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07019870 · National University Hospital, Singapore Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2027
🇸🇬 SG

Who might be able to join this trial: - People who are of Chinese, Malay, or mixed ethnicity - People who have not been diagnosed with NPC (nasopharyngeal carcinoma, a type of cancer affecting the back of the nose and throat) - People who have a family history of NPC Who may not be able to join: - People who are young...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07033091 · The Institute of Molecular and Translational Medicine, Czech Republic Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2030
🇨🇿 CZ

Who might be able to join this trial: - People who are 40 years of age or older at the time of joining the trial. - People who are able to rinse and gargle independently without assistance. - People who have signed a consent form agreeing to take part in the study, to have molecular and genetic testing done, and to hav...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07040072 · Beijing Tongren Hospital Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 June 2027
🇨🇳 CN

**Who might be able to join this trial:** - You are willing to sign a consent form agreeing to take part - You have head and neck cancer (in the mouth, throat, or voice box area) that has come back or spread to other parts of the body - You are 18 years old or older and are generally able to carry out daily activities...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07059221 · Suzhou Suncadia Biopharmaceuticals Co., Ltd. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 March 2027
🇨🇳 CN

**Who might be able to join this trial:** - People who are able to understand and sign a consent form, and who are willing and able to follow the trial's treatment plan and attend required visits and tests - People who have been diagnosed with advanced or widely spread squamous cell carcinoma (a type of cancer) of the...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07061704 · Sichuan University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 August 2027
🇨🇳 CN

**Who might be able to join this trial:** - People aged between 18 and 80 years old - People who have been diagnosed with locally advanced squamous cell carcinoma of the oesophagus (a specific type of oesophageal cancer), with or without cancer that has spread to lymph nodes in the neck - People who are able to provid...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07063212 · Memorial Sloan Kettering Cancer Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 2 January 2028
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed (confirmed by a lab test on a tissue or cell sample) with squamous cell carcinoma of the head and neck, specifically starting in the sinuses, nasal cavity, mouth, throat, voice box, or nearby areas — other locations may be considered at the doc...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07065630 · University of Chicago Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 13 August 2029
🇺🇸 US

**Who might be able to join this trial:** - People who have been confirmed by a pathology test to have locally advanced (but not spread to distant parts of the body) squamous cell carcinoma (a type of cancer) in one of these areas: the mouth, throat (including the oropharynx, hypopharynx, or nasopharynx), voice box, o...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07068711 · Marmara University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 25 June 2026
Turkey (Türkiye)

**Who might be able to join this trial:** - People aged 18 years or older - People who have been diagnosed with head and neck cancer - People who are receiving radiotherapy treatment at Marmara University Pendik Training and Research Hospital, Radiation Oncology Clinic - People who are willing to take part and can sign...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07070479 · Ming-Yuan Chen Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 January 2027
🇨🇳 CN

**Who might be able to join this trial:** - People who have been confirmed by tissue or cell testing to have recurrent or metastatic nasopharyngeal carcinoma of a specific non-keratinizing type (WHO type II or III). - People aged between 18 and 70 years. - People with a general health/activity score of 0 or 1 on a sta...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07071727 · The Netherlands Cancer Institute Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2028
🇳🇱 NL

**Who might be able to join this trial:** - People who have been diagnosed with an intermediate to high grade soft tissue sarcoma (a type of cancer in the body's connective tissues) located in the head and neck, trunk, chest wall, or limbs, where the standard treatment plan includes both radiation therapy and surgery...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07081074 · West China Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 23 May 2026
🇨🇳 CN

Who might be able to join this trial: - People who have been diagnosed with a cancerous tumour in the head or neck area that has not spread to other parts of the body - People whose doctors have determined they are suitable to receive high-dose radiation treatment, either as their main treatment or after having surgery...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07085988 · Jiangxi Provincial Cancer Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2025
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with nasopharyngeal carcinoma (a type of cancer in the back of the nose and throat) confirmed by a laboratory tissue test - People whose cancer is at a stage classified as Stage II, III, or IVa, and whose treatment plan includes receiving chemo...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07086638 · West China Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 May 2026
🇨🇳 CN

Who might be able to join this trial: - People who have been diagnosed with a cancerous tumour in the head or neck area that has not spread to other parts of the body - People whose doctors have determined that high-dose radiation treatment is appropriate for them, either as their main treatment or after surgery to rem...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07088211 · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong Univ... Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 August 2027
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 75 years, of any gender - People whose cancer has been confirmed by laboratory testing (biopsy or cell sample) as a specific type of head and neck cancer called squamous cell carcinoma, affecting the throat, mouth, voice box, or lower throat area, that cann...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07094685 · University of Michigan Rogel Cancer Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 August 2027
🇺🇸 US

**Who might be able to join this trial:** - Adults aged 18 or older - People whose tumour tissue tests show a PD-L1 combined positive score (CPS) of 1 or higher (a measure of a protein on cancer cells) - People diagnosed with advanced head and neck squamous cell cancer (HNSCC) affecting the mouth, throat, or related a...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07101432 · M.D. Anderson Cancer Center Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 31 December 2027
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with head and neck cancer (confirmed by a tissue test), where the cancer is either advanced and cannot be surgically removed, or has spread to up to 5 sites in the body, and has come back or gotten worse after standard treatments, has no standard tr...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07101744 · Sun Yat-sen University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 16 July 2028
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 70 years - People with a good general health and activity level, rated 0 or 1 on a standard medical scale used to measure how much a condition affects daily activities (confirm with trial site) - People who have been diagnosed with nasopharyngeal carcinoma...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07108517 · Centre for Research and Technology Hellas Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 November 2025
🇬🇷 GR

**Who might be able to join this trial:** - You are 18 years of age or older - You have been diagnosed with breast cancer, colorectal cancer (bowel cancer), or head and neck cancer - You have finished all your planned chemotherapy treatment and any related hospital stays - Your cancer was first diagnosed no more than 5...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07110142 · Case Comprehensive Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2028
🇺🇸 US

Who might be able to join this trial: - People who are 18 years of age or older - People who have not previously had head and neck cancer - People who have not previously had radiation therapy - People who are planned to have surgery to remove up to half of their tongue (a partial or hemi-glossectomy), with immediate r...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07124520 · Memorial Sloan Kettering Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 7 August 2028
🇺🇸 US

Who might be able to join this trial: - People who are 18 years of age or older - People who are scheduled to have primary (first-time) surgery for cancer of the tongue, involving a partial tongue removal (types 1 to 3), with any method of closing or rebuilding the area Who may not be able to join: - People who have p...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07131566 · Lars Olaf Cardell Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2031
🇸🇪 SE

Who might be able to join this trial: - People who have been diagnosed with a primary cancer of the head and neck (a type called HNSCC) - People whose surgery, which involves removing the tumour along with either a full or partial removal of nearby lymph nodes in the neck, is being performed at Karolinska University Ho...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07133958 · Zhujiang Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 March 2027
🇨🇳 CN

**Who might be able to join this trial:** - People diagnosed with locally advanced oral cancer or throat (oropharyngeal) cancer that has reached a certain size or spread to nearby structures, based on standard staging guidelines - People between 18 and 80 years of age - People with no previous history of any other type...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07156227 · National Cancer Institute (NCI) Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 31 May 2029
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with head and neck squamous cell cancer (in the mouth, throat, voice box, or nearby areas) that has come back or is a new cancer in the same region, and cannot be removed by surgery — either because you declined surgery or a specialist determined surg...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07160296 · Renown Health Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 September 2026
🇺🇸 US

Who might be able to join this trial: - Adults aged 18 or older who have been diagnosed with squamous cell carcinoma (a type of cancer) of the head and neck, confirmed by a biopsy - People who are planned to receive chemotherapy combined with radiation therapy as their main treatment or following surgery - People with...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07172256 · Yale University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 February 2031
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with a specific type of head and neck cancer called squamous cell carcinoma of the oropharynx (the middle part of the throat, including the base of the tongue and tonsils), confirmed by a lab test, that has not spread to distant parts of the bo...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07178301 · Northwestern University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 20 March 2030
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with a type of throat cancer (oropharyngeal squamous cell carcinoma) that is linked to the HPV virus, confirmed by a specific laboratory test called HPV in situ hybridization. - People who have not received any prior treatment for this cancer (...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07178847 · Centre Jean Perrin Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2029
🇫🇷 FR

**Who might be able to join this trial:** - People who are already participating in the related NeckTAR study - People who have signed a written consent form specifically for the NeckTAR-IN study - People who are registered with the French social security system **Who may not be able to join:** - No specific exclusion...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07180901 · Centre hospitalier de l'Université de Montréal (CHUM) Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 21 October 2026
🇨🇦 CA

Who might be able to join this trial: - Adults aged 18 or older. - People with a laboratory-confirmed diagnosis of squamous cell carcinoma (a type of cancer) in the mouth or voice box (larynx). - People diagnosed between July 2024 and September 2026. - People whose treatment plan includes surgery as the main intended t...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07188584 · Ming-Yuan Chen Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 December 2030
🇨🇳 CN

**Who might be able to join this trial:** - People aged between 18 and 70 years old. - People who have signed a consent form and are willing and able to attend appointments, follow the treatment schedule, and complete required tests as outlined in the study plan. - People newly diagnosed with cancer that has spread to...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07189897 · Kiranya Arnold Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 September 2027
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 to 89 years old (male or female) who are willing and able to follow the study procedures and attend follow-up appointments - People who have a confirmed diagnosis of head and neck cancer through a biopsy, or a suspected head and neck cancer that is awaiting ti...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT07190573 · Samsung Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 January 2030
🇰🇷 KR

**Who might be able to join this trial:** - Adults aged 20 years or older - People who have been diagnosed with head and neck cancer confirmed by tissue testing, including cancers of the mouth, throat, voice box, nasal cavity, or salivary glands — including those diagnosed at another hospital but confirmed at Samsung M...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07195734 · National Cancer Institute (NCI) Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 February 2033
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed through laboratory testing (tissue or cell sample) with squamous cell carcinoma of the head and neck (a specific type of cancer) that has come back or not fully responded to treatment, located in the mouth, throat, voice box, or lower throat ar...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07201337 · Sun Yat-sen University Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 17 November 2029
🇨🇳 CN

Who might be able to join this trial: - People who have been newly diagnosed with a specific type of nasopharyngeal cancer (a non-keratinizing type that has not spread to distant parts of the body) and have not yet received any treatment for it - People aged between 18 and 70 years old - People who are generally well e...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07203911 · Tobias Todsen Not Applicable · 5 countries Recruiting
Recruiting Not Applicable Est. completion 15 September 2027
🇩🇰 DK🇮🇹 IT🇿🇦 ZA🇸🇪 SE🇺🇸 US

Who might be able to join this trial: - You have been diagnosed with oral cancer (a specific type called squamous cell carcinoma) at an early to intermediate stage (T1-T3), confirmed by a biopsy. - You are already scheduled to have surgery as part of your treatment. Who may not be able to join: - You are under 18 year...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07209189 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 October 2030
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with advanced head and neck cancer, or cancers of the sinuses, nasolacrimal (tear duct) area, or skull base, confirmed by a tissue biopsy. - People whose cancer is an HPV-independent head and neck squamous cell cancer at a certain stage (cT2–cT...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07213934 · University of Cincinnati Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2030
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed (through laboratory testing of a tissue or cell sample) with head and neck squamous cell cancer that has come back, specifically in the mouth, voice box, lower throat, or the back of the throat (HPV-negative type only). - People whose doctors consid...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07214987 · Massachusetts General Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2027
🇺🇸 US

**Who might be able to join this trial:** - People who have been newly diagnosed with squamous cell carcinoma (a specific type of cancer) in areas such as the mouth, throat, voice box, nasal cavities, or a related area where the original source of the cancer is unknown. - People whose cancer is at stage III or stage I...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07215169 · Lund University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇸🇪 SE

Who might be able to join this trial: - People who have previously been diagnosed with cancer of the oropharynx (the middle part of the throat, including the back of the mouth and base of the tongue) — all cancer cell types are accepted - People who completed curative treatment using radiation therapy (with or without...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07219212 · Johnson & Johnson Enterprise Innovation Inc. Phase 1 · 3 countries Recruiting
Recruiting Phase 1 Est. completion 14 July 2028
🇫🇷 FR🇯🇵 JP🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with a specific type of cancer called squamous cell carcinoma in the head and neck area — specifically in the mouth, throat (a type that tests negative for a protein called p16), the lower part of the throat near the voice box, or the upper part of...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07225855 · City of Hope Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 24 November 2027
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with head and neck cancer that has not spread to other parts of the body - People aged 60 years or older - People who are planned to receive radiation treatment aimed at curing the cancer, either on its own or combined with chemotherapy, whether bef...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07232524 · Sichuan Baili Pharmaceutical Co., Ltd. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 November 2027
🇨🇳 CN

Who might be able to join this trial: - People who are willing to sign a consent form and follow the study requirements - People of any gender - People aged 18 to 75 years (for Phase Ia of the study) or aged 18 and older (for Phase Ib of the study) - People with a life expectancy of at least 3 months - People diagnosed...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07241039 · AbbVie Phase 1 · 4 countries Recruiting
Recruiting Phase 1 Est. completion 1 April 2029
🇨🇦 CA🇮🇱 IL🇯🇵 JP🇺🇸 US

**Who might be able to join this trial:** - People whose cancer has continued to grow or spread during or after standard treatment, or for whom no curative treatment is available (including those who have refused standard treatment, been considered unsuitable for it, or were unable to tolerate it). - People who have p...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07242859 · Christina Milad Lobos Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 November 2025
🇪🇬 EG

Who might be able to join this trial: - Adults aged 18 years or older - People diagnosed with squamous cell carcinoma (a type of cancer) in the head and neck area, where the cancer has not spread from another part of the body - People who are well enough to undergo radiotherapy, as measured by a standard health scale (...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07248956 · Eye & ENT Hospital of Fudan University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 November 2027
🇨🇳 CN

**Who might be able to join this trial:** - People who are willing to sign a written consent form agreeing to take part - People aged 18 to 75 years old - People who have not yet received any treatment for their cancer - People who have been diagnosed with a certain stage of throat cancer (specifically hypopharyngeal c...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07254585 · CSPC Megalith Biopharmaceutical Co.,Ltd. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 June 2026
🇨🇳 CN

Who might be able to join this trial: - People aged 18 to 75 years old, of any gender - People who have been diagnosed through a biopsy with head and neck squamous cell carcinoma that has come back or spread, and for whom major surgery or combined chemotherapy and radiation treatment is not an option - For the combinat...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07260344 · Anil Chaturvedi Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 January 2028
🇹🇼 TW

Who might be able to join this trial: - People between the ages of 30 and 80 years old. - People who have a visible pre-cancerous lesion in the mouth that is at least 1 centimetre across at its widest point. Who may not be able to join: - People who are currently receiving cancer treatment, or who have had cancer with...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07264075 · Groupe Oncologie Radiotherapie Tete et Cou Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 May 2030
🇫🇷 FR

Who might be able to join this trial: - You must be able to give written consent to participate voluntarily. - You must be between 18 and 79 years old at the time of joining the trial. - You must be generally well enough to carry out light activity and care for yourself (a doctor will assess this using a standard scori...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07274852 · Sichuan Baili Pharmaceutical Co., Ltd. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 December 2027
🇨🇳 CN

**Who might be able to join this trial:** - People who are willing to sign a consent form and follow the study requirements - People of any gender - People aged 18 to 75 years (for the Phase Ia part of the study) or aged 18 and older (for the Phase Ib part) - People with a life expectancy of at least 3 months - People...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07282483 · West China Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 August 2026
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with a cancer of the head or neck area that has not spread to other parts of the body (confirmed by a biopsy or lab test) - You are between 18 and 65 years old (inclusive) - You are reasonably able to carry out daily activities — your overall physical...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07285564 · Centre Henri Becquerel Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 March 2026
🇫🇷 FR

Who might be able to join this trial: - People who have signed a consent form agreeing to take part in the study - Adults (men or women) aged 18 or older - People who have a cancerous tumour located in the mouth, throat (back of mouth or lower throat), voice box, sinuses, or salivary glands, where the cancer has not sp...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07290621 · University of Chicago Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 February 2030
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with a specific type of throat/mouth cancer (head and neck squamous cell carcinoma of the oropharynx) that has tested positive for a virus called HPV16, confirmed through specific laboratory tests. - People who are at least 18 years old. - People wh...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07293013 · Chiayi Christian Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇹🇼 TW

Who might be able to join this trial: - People who are 20 years of age or older - People who have been diagnosed with a primary (original, not returned) cancer located in the head and neck area, and who are preparing to receive radiation therapy or a combination of radiation and chemotherapy together - People whose tot...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07296250 · Chang Gung Memorial Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 July 2026
🇹🇼 TW

Who might be able to join this trial: - Adults between 18 and 90 years of age - People who have been diagnosed with a type of head and neck cancer called squamous cell carcinoma, confirmed through laboratory testing of tissue samples - People who have completed surgery for their cancer, been identified as having high-r...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07303023 · Fudan University Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 September 2028
🇨🇳 CN

**Who might be able to join this trial:** - People aged between 18 and 70 years old - People who have been diagnosed with nasopharyngeal carcinoma (a type of cancer in the back of the nose and throat), confirmed by laboratory testing, classified as WHO type I, II, or III - People whose cancer is at a stage that has no...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07318220 · University of Miami Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 August 2027
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 to 80 years old - People diagnosed with a specific type of head and neck cancer (squamous cell carcinoma) that has not spread to other parts of the body, originating in areas such as the mouth, throat, voice box, or nasal passages - People whose treatment plan...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07326358 · Ruijin Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇨🇳 CN

Who might be able to join this trial: - People who are 18 years of age or older - People who have had a standard camera examination of the nose, throat, and voice box (called a nasopharyngolaryngoscopy) - People who had a tissue sample (biopsy) taken and received a confirmed diagnosis from that sample - People who have...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07327216 · Affiliated Hospital of Guangdong Medical University Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 July 2026
🇨🇳 CN

**Who might be able to join this trial:** - People diagnosed with Stage III to IVa nasopharyngeal cancer (a type of cancer at the back of the nose/throat), confirmed by a pathology test at a major hospital - People who have not previously received any radiotherapy, chemotherapy, surgery, immunotherapy, or targeted the...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07328347 · University Medical Center Goettingen Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2026
🇩🇪 DE

Who might be able to join this trial: - People aged 18 or older who have been diagnosed with head and neck cancer and are well enough to complete a questionnaire - Dentists currently practicing in Germany who are listed in the OAK-Verlag address database Who may not be able to join: - People who do not agree to take p...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07328854 · Ming-Yuan Chen Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 30 June 2030
🇨🇳 CN

Who might be able to join this trial: - People who have been fully informed about the study and have signed a consent form agreeing to take part - People aged between 18 and 75 years - People who have been confirmed by tissue testing to have a specific type of nasopharyngeal cancer (a cancer at the back of the nose/thr...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07337161 · David Palma Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2030
🇨🇦 CA

**Who might be able to join this trial:** - People aged 18 or older - People who are able to give informed consent to participate - People who are well enough to carry out everyday activities with little or no limitation (this is measured using a standard scale called ECOG, scores 0–2) - People whose cancer is being t...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07339774 · West China Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 October 2026
🇨🇳 CN

Who might be able to join this trial: - People who have been diagnosed with a head and neck cancer that has not spread to other parts of the body - People aged between 18 and 65 years old (inclusive) - People whose general health and ability to carry out daily activities meets a certain level, as measured by a standard...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07340515 · Man Hu Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 31 December 2031
🇨🇳 CN

Who might be able to join this trial: - Adults between 18 and 70 years of age - People with a laboratory-confirmed diagnosis of nasopharyngeal carcinoma (a type of cancer at the back of the nose and throat), specifically WHO type II or III - People whose cancer is classified as high-risk locally advanced disease, meani...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07343271 · University Hospital, Strasbourg, France Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2026
🇫🇷 FR

Who might be able to join this trial: - People who are 18 years of age or older - People who have been diagnosed with a specific type of cancer (squamous cell carcinoma) affecting the mouth or throat area, confirmed by a laboratory analysis of a tissue sample - People who have had a physical examination including a cam...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07343596 · University of Wisconsin, Madison Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2027
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 or older at the time of registration - People with a general health/activity level rated at 0, 2, or anywhere in between on a standard medical scale (called ECOG), assessed within the 30 days before joining - People with a suspected stage II to IVB oral cavity...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07348887 · University Health Network, Toronto Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2029
🇨🇦 CA

Who might be able to join this trial: - Adults aged 18 or older - People who have been diagnosed with squamous cell carcinoma (a type of cancer) in the head and neck area, confirmed by a tissue test - People whose treatment plan involves treating both sides of the neck - People whose treatment plan leaves at least one...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07353671 · West China Hospital Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 31 December 2026
🇨🇳 CN

Who might be able to join this trial: - Adults between 18 and 80 years old, of any gender - People who have been diagnosed with head and neck cancer (including nasopharyngeal carcinoma) confirmed by laboratory testing of tissue, and who need radiation therapy as a main treatment or after surgery - People whose general...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07362979 · Sun Yat-sen University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 12 March 2029
🇨🇳 CN

**Who might be able to join this trial:** - People aged between 18 and 70 years, who are male or non-pregnant female - People whose biopsy results have confirmed a specific type of nasopharyngeal cancer (non-keratinizing carcinoma, also called WHO type II or III) - People whose cancer is at a locally advanced stage —...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07371611 · Qunxing Li,MD Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 31 December 2030
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 75 years old at the time of joining the trial - People who are generally able to carry out normal daily activities with little to no limitation (as assessed by a standard medical scale called ECOG, with a score of 0 or 1) - People whose cancer has been conf...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07392580 · University of Miami Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 September 2031
🇺🇸 US

**Who might be able to join this trial:** - Adults aged 18 or older, of any gender - People who have previously been treated for squamous cell cancer of the voice box (larynx) with radiation therapy - People who have cancer that has come back, confirmed by a tissue sample (biopsy) — if no stored tissue sample is avail...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07396259 · Chang Gung Memorial Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2030
🇹🇼 TW

Who might be able to join this trial: **For people with cancer:** - Adults aged 18 or older who have been diagnosed with Head and Neck Cancer and are planning to receive immunotherapy treatment - People whose doctor has assessed their life expectancy to be at least 3 months - People who have a tissue biopsy available,...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07398664 · West China Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 15 June 2028
🇨🇳 CN

Who might be able to join this trial: - People aged 18 to 79 years old. - People who have been diagnosed with a head or neck cancer confirmed by laboratory testing — this includes cancers of the nasopharynx, mouth, throat, voice box, salivary glands, nasal cavity, sinuses, and similar areas. - People whose cancer has s...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07402525 · Second Affiliated Hospital, School of Medicine, Zhejiang University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 January 2031
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 70 years old (any gender) - People who have not previously received radiation therapy, chemotherapy, or targeted therapy for their cancer - People whose surgeon was able to fully remove the tumor, with no remaining cancer found when the removed tissue was e...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07405645 · University of Virginia Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2028
🇺🇸 US

Who might be able to join this trial: - You are a man or woman between 18 and 85 years old - You have been diagnosed with a cancer in the head, neck, or shoulder/upper chest area — this includes cancers of the nose, sinuses, lips, mouth, salivary glands, throat, voice box, skin, thyroid, eye, nasopharynx, upper lung (i...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07407582 · University of Arizona Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 April 2028
🇺🇸 US

**Who might be able to join this trial:** - You must be willing and able to give your consent to participate before any study activities begin. - You must be at least 18 years old (male or female) at the time you sign the consent form. - You must be generally healthy and able to carry out normal daily activities, with...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07408063 · University Health Network, Toronto Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 June 2030
🇨🇦 CA

**Who might be able to join this trial:** - People aged 18 or older who have given written consent to participate - People who have been diagnosed with a specific type of head and neck cancer called squamous cell carcinoma (confirmed by a tissue or cell sample), where the cancer has spread or come back and cannot be c...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07412314 · Guangzhou Concord Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 10 March 2028
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with squamous cell carcinoma (a type of cancer) of the nasopharynx (the upper part of the throat, behind the nose), confirmed by a biopsy, at a certain stage of advancement — either at stage T2b or higher, and/or where the cancer has spread to...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07423078 · Matthew Spector Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 April 2029
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with squamous cell carcinoma (a type of cancer) of the larynx (voice box) or hypopharynx (lower throat), confirmed by a laboratory test, who have not yet received any treatment for it - People whose cancer is classified as Stage III or Stage IV...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07444723 · National Institute of Diabetes and Digestive and Kidney Diseases (NIDD... Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 5 February 2035
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 to 100 years old - People who are willing to have parathyroid surgery at the NIH Clinical Center - People who have been diagnosed with sporadic primary hyperparathyroidism (a condition where one or more parathyroid glands produce too much parathyroid hormone)...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07448727 · University of Rome Tor Vergata Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇮🇹 IT

**Who might be able to join this trial:** - People who have been diagnosed through a tissue sample (biopsy) with head and neck cancer that has come back or spread to other parts of the body, cannot be treated with surgery or radiation therapy to remove or cure it, and are being considered for their first round of drug-...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07457346 · Second Affiliated Hospital, School of Medicine, Zhejiang University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 August 2028
🇨🇳 CN

Who might be able to join this trial: - People with a good general level of physical functioning, able to carry out normal daily activities with little or no limitation (as measured by a standard medical scale called ECOG 0–1). - People who have been confirmed by laboratory testing to have Stage III or Stage IVA squamo...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07460765 · Vanderbilt-Ingram Cancer Center Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 April 2030
🇺🇸 US

**Who might be able to join this trial:** - People who have given written consent to participate - People aged 18 or older - People who have head and neck squamous cell cancer (a type of mouth, throat, or related cancer) confirmed by biopsy, shown on imaging as a returning cancer, or being surgically removed as a susp...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07465276 · Dana-Farber Cancer Institute Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 April 2028
🇺🇸 US

**Who might be able to join this trial:** - People who have been newly diagnosed with a specific type of head and neck cancer (squamous cell carcinoma) that started in the mouth, throat, voice box, or lower throat area, and have not yet received any treatment for it. - People whose cancer has been confirmed by a lab t...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07467083 · West China Hospital Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 March 2027
🇨🇳 CN

Who might be able to join this trial: - People who have been diagnosed with a cancerous tumour in the head or neck area that has not spread to other parts of the body, confirmed through laboratory testing of tissue. - People aged 18 or older who are planned to receive radiation therapy after surgery, or radiation thera...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07475780 · M.D. Anderson Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 April 2029
🇺🇸 US

**Who might be able to join this trial:** - People who are older than 18 years and are either not suitable for surgery or do not wish to have surgery - People who are healthy enough to undergo a procedure using local anaesthetic, with or without light sedation - People who are able to understand the study information...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07485296 · Gruppo Oncologico del Nord-Ovest Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2030
🇮🇹 IT

Who might be able to join this trial: - People who are willing and able to give informed consent to take part in the trial and its procedures - People who have been confirmed through a tissue sample (biopsy) to have head and neck squamous cell cancer (a specific type of head and neck cancer) - People whose head and nec...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07491536 · University of Pavia Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇮🇹 IT

**Who might be able to join this trial:** - You are 18 years old or older - You have been diagnosed with mouth sores (oral mucositis) caused by radiation therapy and/or chemotherapy, rated as grade 1, 2, or 3 on a standard medical scale - You are currently receiving cancer treatment for a solid tumour, especially a hea...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07492914 · West China Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - Adults aged 18 or older, of any gender - People who have been diagnosed through laboratory testing with a type of head and neck cancer called squamous cell carcinoma (not including cancers of the nasopharynx, salivary glands, or thyroid), where a surgeon has assessed the tum...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07497607 · Sara Medek Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 13 May 2031
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with squamous cell carcinoma of the oropharynx (a type of throat cancer) confirmed by a tissue or cell sample, and who are planned to receive chemotherapy combined with radiation as their main treatment - People whose throat cancer has tested p...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07501650 · Thomas Jefferson University Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 March 2027
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with head and neck cancer that has come back or spread, is not linked to HPV, and has a specific protein marker score above 1 (confirmed by lab testing). - People whose cancer has at least one tumour that can be seen and measured by ultrasound, and...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07508319 · European Institute of Oncology Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇮🇹 IT

Who might be able to join this trial: - People who have been diagnosed with abnormal cell changes (dysplasia) in the voice box (larynx), confirmed by a tissue sample analysis. - People who are over 18 years of age and have given their informed consent to participate in research. Who may not be able to join: - People w...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07509619 · National Taiwan University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 May 2026
🇹🇼 TW

Who might be able to join this trial: - You are a healthy adult between 20 and 70 years old - You do not have trismus (difficulty opening your mouth or jaw stiffness) - You have never had an injury or surgery on your head, neck, or shoulders - You have never received radiation therapy or chemotherapy for head and neck...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07513389 · Medical University of South Carolina Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 July 2029
🇺🇸 US

Who might be able to join this trial: - People who are willing and able to sign a consent form and take part in all study activities for the full duration of the trial. - People aged 18 or older (there is no upper age limit). - People who have been diagnosed with squamous cell carcinoma (a type of cancer) confirmed by...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07524452 · Ming-Yuan Chen Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 28 February 2031
🇨🇳 CN

**Who might be able to join this trial:** - People who are willing to voluntarily sign a consent form agreeing to take part in the study - People who have been newly diagnosed (not yet treated) with a type of head and neck cancer called squamous cell carcinoma — affecting the mouth, throat, voice box, or lower throat...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07528495 · All India Institute of Medical Sciences Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 30 December 2027
🇮🇳 IN

**Who might be able to join this trial:** - People aged 18 to 69 years old - People who have been diagnosed with a specific type of mouth cancer (called squamous cell carcinoma) at stages pT1 through pT4, confirmed by a tissue test, and who are having surgery to remove the cancer along with lymph nodes in the neck - P...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07545967 · West China Hospital Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 July 2027
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 75 years old, with a life expectancy of at least 3 months. - People who have been diagnosed with a specific type of head and neck cancer (squamous cell carcinoma), confirmed by a tissue sample (biopsy), where the cancer started in the mouth, throat, voice b...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07546045 · Christian Simon Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2028
🇨🇭 CH

**Who might be able to join this trial:** - People who are scheduled to have a specific type of robotic-assisted surgery (using the Da Vinci Xi or SP robotic system) to remove a primary (first-time) tumour in areas such as the base of the tongue, throat, voicebox, or surrounding structures — at certain early-to-modera...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07546383 · The Second Affiliated Hospital of Hainan Medical University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2027
🇨🇳 CN

Who might be able to join this trial: - People who are able to give written consent before any trial procedures begin - People aged 18 to 75, of any gender - People whose general physical functioning is rated at a level showing they are able to carry out at least some daily activities (a standard performance scale scor...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07548268 · Tobias Todsen Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2026
🇩🇰 DK

**Who might be able to join this trial:** - People who have been referred to an outpatient cancer clinic because a scan (such as an MRI, CT, or PET/CT) showed something that may be cancer in the back of the throat or tonsil area - People who have been referred because a doctor noticed something suspicious during an exa...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07562100 · Taipei Veterans General Hospital, Taiwan Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 July 2028
🇹🇼 TW

Who might be able to join this trial: - Adults who are older than 20 years old and younger than 70 years old - People who have recently been diagnosed with ovarian cancer and are scheduled to start cancer-related treatment - People who are able to use a mobile phone - People who are willing to sign a consent form after...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07567235 · West China Hospital Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 March 2027
🇨🇳 CN

Who might be able to join this trial: - People aged 18 to 75 years old at the time of screening, of any gender - People who have been diagnosed with head and neck squamous cell carcinoma (a specific type of cancer affecting the head and neck area, but not the nasopharynx) confirmed through a tissue sample, and who are...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07573956 · All India Institute of Medical Sciences Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 30 June 2028
🇮🇳 IN

**Who might be able to join this trial:** - People who have been diagnosed with a specific type of cancer called squamous cell carcinoma in the mouth, throat, voice box, or lower throat area, at any stage (T1–T4), and whose cancer has at least one of these features: cancer found in nearby lymph nodes, cancer growing a...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07580300 · Oslo University Hospital Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 28 April 2030
🇳🇴 NO

**Who might be able to join this trial:** - You are willing and able to sign a consent form to take part in the study - You are 40 years of age or older - You have been diagnosed with a specific type of cancer called squamous cell carcinoma, confirmed by a tissue or cell sample, located in the mouth, throat, voice box,...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07590024 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 31 December 2030
🇨🇳 CN

Who might be able to join this trial: - People aged 18 to 65 years, of any sex - People who have been diagnosed with a specific type of nasopharyngeal cancer (cancer in the back of the nose/throat) that has been confirmed by a tissue test, is linked to a virus called EBV, is non-spreading, and is of the non-keratinizin...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07601737 · Shanghai General Hospital, Shanghai Jiao Tong University School of Med... Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 April 2028
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 75 years old - People who have been diagnosed with a specific type of cancer called squamous cell carcinoma in the head and neck area (such as the mouth, throat, voice box, or lower throat), at an advanced but not the most severe stage (Stage III to IVB) -...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07617805 · Beijing Biotech Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 14 March 2027
🇨🇳 CN

Who might be able to join this trial: - People aged 18 to 75 years at the time of signing the consent form - People who have been diagnosed (through lab testing of tissue or cells) with squamous cell carcinoma of the mouth, throat, voice box, or the area connecting the throat to the oesophagus, where the cancer has com...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07618078 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2031
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 75 years, of any gender - People who have been diagnosed with a specific type of nasopharyngeal cancer (cancer at the back of the nose/throat) confirmed by laboratory testing, and whose cancer tests positive for a marker called EBER - People whose cancer ha...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07622381 · Tianjin Medical University Cancer Institute and Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 August 2026
🇨🇳 CN

Who might be able to join this trial: - People who have been diagnosed with head and neck cancer according to specific Chinese medical guidelines (the CSCO 2023 guidelines for head and neck tumours) - People who are planned to have surgery for their head and neck cancer - People who are older than 18 years of age - Peo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07622914 · University of Oklahoma Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 March 2027
🇺🇸 US

Who might be able to join this trial: - People who are 18 years of age or older - People who have recently been diagnosed with a type of cancer called squamous cell carcinoma in one of these areas: the sinuses, nasal cavity, mouth, tongue, voice box, or throat (including the upper, middle, or lower sections of the thro...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07635641 · Istituto Clinico Humanitas Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2031
🇮🇹 IT

Who might be able to join this trial: - People who are 18 years of age or older - People whose ability to carry out daily activities is within a certain range of functioning, rated 0 to 2 on a standard medical scale (confirm with trial site) - People whose head and neck cancer recurrence has been confirmed through tiss...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07654647 · Tishreen University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2026
Syria

Who might be able to join this trial: - People aged 18 years or older - People who have bone defects in the face caused by cysts or tumours that have broken down bone tissue - People who have facial differences — either present from birth or developed over time — that involve missing or uneven bone structure - People w...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07662681 · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong Univ... Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 July 2028
🇨🇳 CN

**Who might be able to join this trial:** - Adults aged 18 or older - People with a confirmed diagnosis (through tissue or cell testing) of one of the following cancers that cannot be surgically removed, has come back, or has spread: soft tissue sarcoma, malignant melanoma, adenoid cystic carcinoma, or salivary gland...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07686211 · Vanderbilt University Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2029
🇺🇸 US

Who might be able to join this trial: - Resident physicians in their first through fifth years after medical school graduation (no age limit applies) - Surgical fellows (doctors completing advanced specialist surgical training) - Attending physicians (fully qualified, independent doctors) - People with prior experience...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07686575 · Zhujiang Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 August 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed by a pathologist (through tissue testing) with either oral cancer or throat cancer (specifically squamous cell carcinoma type) - People whose cancer has been classified as locally advanced — this includes certain Stage III or Stage IVA mouth ca...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07689019 · Buddhist Tzu Chi General Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇹🇼 TW

Who might be able to join this trial: - Adults between 30 and 85 years of age - People who have been diagnosed with head and neck cancer, confirmed through laboratory testing of tissue samples - People who are scheduled to receive chemotherapy and radiation therapy at the same time - People who are able to communicate...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07706985 · Sun Yat-sen University Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 20 July 2030
🇨🇳 CN

**Who might be able to join this trial:** - People aged between 18 and 70 years old, of any gender - People who have been diagnosed with nasopharyngeal carcinoma (a type of cancer at the back of the nose/throat), confirmed through a tissue or cell sample - People whose cancer has been classified as Stage III or Stage...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07712120 · University of Turin, Italy Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 23 February 2026
🇮🇹 IT

**Who might be able to join this trial:** - People who have been diagnosed with head and neck cancer and are scheduled to have surgery to remove tissue in the mouth or throat area, with or without a reconstructive procedure using tissue from another part of the body. - People who are 18 years of age or older at the tim...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07726199 · Kolhapur Cancer Centre - Cancer Centers of America Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2030
🇮🇳 IN

Who might be able to join this trial: - People who are older than 21 years of age - People who have been diagnosed with squamous cell carcinoma (a specific type of cancer) of the oral cavity (mouth), confirmed through a tissue sample test - People whose cancer is classified as stage T1 to T4, with no spread to lymph no...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Advocacy and support in Australia

Organisations that can offer information, support, or connection for Head and Neck Cancer. Where more than one is listed, they serve different needs or regions, so choose whichever fits your situation.

Head and Neck Cancer Australia is the national body for head and neck cancer support.

This is a starting point, not medical advice or an endorsement. Contact details change; search the organisation name to find its current website.